Urothelial Cancer

1. Yonese I, Numao N, Inamura K, Yoneoka Y, Fujiwara R, Yasuda Y, Oguchi T, Yamamoto S, Yuasa T, Yonese J. A case of neoadjuvant chemotherapy‐resistant muscle‐invasive bladder cancer that markedly responded to pembrolizumab before conversion radical cystectomy. IJU Case Reports. 2023 Nov 12;7(1):64-67.
2. Oki R, Urasaki T, Ueki A, Inamura K, Komai Y, Takahashi S, Yonese J, Yuasa T. A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome. IJU Case Rep, 2022 https://doi.org/10.1002/iju5.12542
3. Fujiwara M, Yokoyama M, Toide M, Fujiwara R, Tanaka H, Oguchi T, Komai Y, Yoshida S, Matsuoka Y, Numao N, Yamamoto S, Fukui I, Yonese J, Fujii Y. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study. Jpn J Clin Oncol. 2023 Mar 7;53(3):263-269. doi: 10.1093/jjco/hyac190.
4. Komai Y, Nakajima K, Saito K, Tomioka Y, Masuda H, Ogawa A, Yonese J, Kobayashi E, Ito M. Development of a New Two-Arm Transurethral Surgical System for En Bloc Resection of Bladder Tumor: A Preclinical Study. J Endourol. 2023 Feb;37(2):165-170. doi: 10.1089/end.2021.0917.
5. Une M, Fujiwara R, Ueki A, Oki R, Urasaki T, Inamura K, Takahashi S, Yonese J, Yuasa T. A case of sequential medical therapy for advanced ureteral cancer in Li–Fraumeni syndrome. IJU Case Report. 2023 Jul 13;6(5):286-289.

Renal Cell Cancer

6. Takemura K, Navani V, Heng DYC, Ernst MS. Prognostic Factors in Advanced Renal Cell Carcinoma. In: McKay RR, Singer EA. (eds) Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma. Springer, Cham;2023 Nov 2. https://doi.org/10.1007/978-3-031-40901-1_10
7. Takemura K, Ernst MS, Navani V, Wells JC, Bakouny Z, Donskov F, Basappa NS, Wood LA, Meza L, Pal SK, Szabados B, Powles T, Beuselinck B, McKay RR, Lee JL, Ernst DS, Kapoor A, Yuasa T, Choueiri TK, Heng DYC. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2023 Oct 30:S2588-9311(23)00217-1. doi: 10.1016/j.euo.2023.10.002. Online ahead of print.PMID: 37914579
8. Lemelin A, Takemura K, Heng DYC, Ernst MS. Prognostic Models in Metastatic Renal Cell Carcinoma. Hematol Oncol Clin North Am. 2023 Jun 1:S0889-8588(23)00050-3. doi: 10.1016/j.hoc.2023.04.016. Online ahead of print.
9. Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee JL, Li H, Agarwal N, Alva AS, Hansen AR, Basappa NS, Szabados B, Powles T, Tran B, Hocking CM, Beuselinck B, Yuasa T, Choueiri TK, Heng DYC. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. J Urol. 2023 Apr;209(4):701-709. doi: 10.1097/JU.0000000000003132. Epub 2022 Dec 27.
10. Takemura K, Ahmed NS, Stukalin I, Gupta M, Ma C, Heng DYC. Trends in health care spending on kidney cancer in the United States, 1996-2016. Cancer. 2023 Jul 15;129(14):2161-2168. doi: 10.1002/cncr.34770. Epub 2023 Apr 2.
11. Yasuda Y, Attawettayanon W, Nguyen JK, Kattar J, Lachowski M, Voros G, Kazama A, Campbell RA, Krishnamurthi V, Eltemamy M, Campbell SC. Neocapsular reconstruction for challenging partial nephrectomy: A feasibility study in a porcine model and recent clinical experience. Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15293. Online ahead of print.
12. Attawettayanon W, Yasuda Y, Zhang JH, Kazama A, Rathi N, Munoz-Lopez C, Lewis K, Shah S, Li J, Emrich Accioly JP, Campbell RA, Shah S, Wood A, Kaouk J, Haber GP, Eltemamy M, Krishnamurthi V, Abouassaly R, Weight C, Derweesh I, Campbell SC. Selective Use of Neoadjuvant Targeted Therapy Is Associated with Greater Achievement of Partial Nephrectomy for High-complexity Renal Masses in a Solitary Kidney. Eur Urol Open Sci. 2023 Jun 10;54:1-9. doi: 10.1016/j.euros.2023.05.016. eCollection 2023 Aug.
13. Munoz-Lopez C, Lewis K, Attawettayanon W, Yasuda Y, Accioly JPE, Rathi N, Lone Z, Boumitri M, Campbell RA, Wood A, Kaouk J, Haber GP, Eltemamy M, Krishnamurthi V, Abouassaly R, Haywood S, Weight C, Campbell SC. Parenchymal volume analysis to assess longitudinal functional decline following partial nephrectomy. BJU Int. 2023 Jul 6. doi: 10.1111/bju.16110. Online ahead of print.
14. Rathi N, Attawettayanon W, Yasuda Y, Lewis K, Roversi G, Shah S, Wood A, Munoz-Lopez C, Palacios DA, Li J, Abdallah N, Schober JP, Strother M, Kutikov A, Uzzo R, Weight CJ, Eltemamy M, Krishnamurthi V, Abouassaly R, Campbell SC. Point of care parenchymal volume analyses to estimate split renal function and predict functional outcomes after radical nephrectomy. Sci Rep. 2023 Apr 17;13(1):6225. doi: 10.1038/s41598-023-33236-6.
15. Munoz-Lopez C, Lewis K, Attawettayanon W, Yasuda Y, Emrich Accioly JP, Rathi N, Lone Z, Boumitri M, Campbell RA, Wood A, Kaouk JH, Haber GP, Eltemamy M, Krishnamurthi V, Abouassaly R, Haywood SC, Weight CJ, Campbell SC. Functional recovery after partial nephrectomy: next generation analysis. BJU Int. 2023 Aug;132(2):202-209. doi: 10.1111/bju.16023. Epub 2023 Apr 19.
16. Yuan JH, Tanaka H, Patil D, Hakimi K, Soliman S, Meagher MF, Saidian A, Walia A, Dhanji S, Liu F, Afari J, Nguyen M, Wang L, Yasuda Y, Saito K, Fujii Y, Master V, Derweesh IH. Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR. Clin Genitourin Cancer. 2023 Aug;21(4):e219-e227. doi: 10.1016/j.clgc.2022.12.002. Epub 2022 Dec 7.
17. Yasuda Y, Zhang JH, Attawettayanon W, Rathi N, Wilkins L, Roversi G, Zhang A, Accioly JPE, Shah S, Munoz-Lopez C, Palacios DA, Hofmann M, Campbell RA, Kaouk J, Haber GP, Eltemamy M, Krishnamurthi V, Abouassaly R, Martin C 3rd, Li J, Weight C, Campbell SC. Comprehensive Management of Renal Masses in Solitary Kidneys. Eur Urol Oncol. 2023 Feb;6(1):84-94. doi: 10.1016/j.euo.2022.11.004. Epub 2022 Dec 12.
18. Tsuzuki T, Ohe C, Osawa T, Yasuda Y, Tanaka T, Anai S, Kimura G, Yamana K, Hatakeyama S, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H. Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study. Pathology. 2023 Feb;55(1):31-39. doi: 10.1016/j.pathol.2022.07.013. Epub 2022 Sep 20.
19. Nguyen MV, Walia A, Saidian A, Puri D, Meagher MF, Hakimi K, Tanaka H, Patil D, Yasuda Y, Saito K, Dhanji S, Cerrato C, Narasimhan R, Perry J, Master V, Fujii Y, Derweesh IH. Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-naïve patients on survival in renal cell carcinoma. BJU Int. 2023 Feb;131(2):219-226. doi: 10.1111/bju.15861. Epub 2022 Aug 13.
20. Campbell SC, Campbell JA, Munoz-Lopez C, Rathi N, Yasuda Y, Attawettayanon W. Every decade counts: a narrative review of functional recovery after partial nephrectomy. BJU Int. 2023 Feb;131(2):165-172. doi: 10.1111/bju.15848. Epub 2022 Jul 25.
21. Yonese J, Hinata N, Masui S, Nakai Y, Shirotake S, Takeuchi A, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Morishima N, Ito H, Uemura H. Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review. Int J Urol. 2023 May 29. doi: 10.1111/iju.15206. Online ahead of print.
22. Hamada K, Komai Y, Fujiwara R, Numao N, Yamamoto S, Yonese J. Doppler ultrasonography as a screening test for the detection of asymptomatic renal artery pseudoaneurysms following partial nephrectomy: A 15-year single-institution experience. Int J Urol. 2023 May;30(5):492-494. doi: 10.1111/iju.15153. Epub 2023 Feb 6.
23. Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, Rosenberg JE, Petrylak DP, Matsangou M, Wu C, Campbell M, Yamashiro M. Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med. 2023 Feb;12(3):2761-2771. doi: 10.1002/cam4.5165. Epub 2022 Sep 2.
24. Fujiwara R, Yuasa T, Kobayashi K, Yoshida T, Kageyama S. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population. Expert Rev Anticancer Ther. 2023 Apr 10:1-9. doi: 10.1080/14737140.2023.2200170. Online ahead of print.
25. Yasuda Y, Fujiwara R, Oguchi T, Komai Y, Numao N, Yamamoto S, Oki R, Urasaki T, Takahashi S, Yonese J, Yuasa T. Prognostic Significance of Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Patients Treated With Immune-checkpoint-inhibitors. Cancer Diagn Progn. 2023 May 3;3(3):327-333. doi: 10.21873/cdp.10219. eCollection 2023 May-Jun.
26. Ernst MS, Navani V, Wells JC, Donskov F, Basappa N, Labaki C, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, McKay RR, Parnis F, Suarez C, Yuasa T, Lalani AK, Alva A, Bjarnason GA, Choueiri TK, Heng DYC. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023 Jan 25:S0302-2838(23)00001-5. doi: 10.1016/j.eururo.2023.01.001. Online ahead of print
27. Aoyama T, Nakano K, Yuasa T, Sugiyama E, Okawa T, Ito K, Azuma K, Hashimoto K, Furutani R, Hiraide M, Kobayashi K, Suzuki K, Tomomatsu J, Tajima M, Sato H, Hama T, Takahashi S. Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma. Sci Rep. 2023 Feb 6;13(1):2099.
28. Fujiwara R, Yuasa T, Yamamoto S, Fujiwara M, Takemura K, Urasaki T, Oki R, Komai Y, Oguchi T, Numao N, Yonese J. Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab. Nutr Cancer. 2023;75(2):670-677. doi: 10.1080/01635581.2022.2152061. Epub 2022 Nov 30

Prostate Cancer

29. Soyano T, Kozuka T, Kashihara K, Murakami Y, Yonese J, Sasamura K, Shimoyachi N, Kashihara T, Yoshioka Y, Oguchi M. Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era? Jpn J Clin Oncol. 2023 Jun 1;53(6):514-521. doi: 10.1093/jjco/hyad019.
30. Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, Komai Y, Numao N, Yuasa T, Inoue M, Ushijima H, Kudo S, Shimano Y, Nakamura Y, Uchida Y, Uehara S, Tanaka H, Yaegashi H, Izumi K, Yokoyama M, Matsuoka Y, Yoshioka Y, Konishi K, Nakanishi K, Nagahara A, Hirakawa A, Koike R, Koga F, Nishimura K, Mizokami A, Yonese J, Kageyama Y, Yoshimura R, Fujii Y. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). BMC Urol. 2023 Mar 6;23(1):33. doi: 10.1186/s12894-023-01202-z.
31. Yasuda Y, Sakurai M, Numao N, Yamamoto S, Yonese J, Yuasa T. Efficacy and safety profile of olaparib for patients with metastatic castration-resistant prostate cancer: A preliminary report of real-world data in a single institution in Japan. Int J Urol. 2023 Nov;30(11):1060-1062. 

Others

32. Kijima T, Fukuda S, Fukushima H, Uehara S, Yasuda Y, Yoshida S, Yokoyama M, Matsuoka Y, Saito K, Fujii Y. The role of multimodal salvage therapy in the management of recurrent adrenocortical carcinoma. Jpn J Clin Oncol. 2023 Apr 29;53(5):436-442. doi: 10.1093/jjco/hyac207.
33. Sugawara E, Shigematsu Y, Amori G, Sugita K, Yonese J, Takeuchi K, Inamura K. CDX2- and PAX8-Expressing Subtypes in Female Urethral Adenocarcinoma: Pathogenesis Insights through Immunohistochemical and Morphological Analyses. Diagnostics (Basel). 2023 Jul 19;13(14):2408. doi: 10.3390/diagnostics13142408.
34. Nakayama I, Shinozaki E, Kawachi H, Sasaki T, Yunokawa M, Tomomatsu J, Yuasa T, Kitazono S, Kobayashi K, Hayakawa K, Ueki A, Takahashi S, Yamaguchi K. Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice. Cancer Med. 2023 Apr;12(7):7932-7940. doi: 10.1002/cam4.5569. Epub 2022 Dec 26.

Editorial comment

35. Yuasa T. Editorial comment to Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment. Int J Urol. 2023 Nov;30(11):1034-1035. 
36. Yuasa T. Editorial comment on Plasma circulating tumor DNA profiling in patients with chemo-refractory germ cell tumors. Int J Urol. 2023 May;30(5):463.
37. Yuasa T. Editorial comment to Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. Int J Urol. 2023 2023 Sep;30(9):721-722.

Operation procedure

1. Komai Y, Yamasaki T, Kanno T, Ohba K, Miki J; Jikei-Kyoto-Osaka-Nagasaki-Ganken Group (J-KONG Group). Management of major venous bleeding during minimally invasive pelvic surgery: A proposed protocol for "What should we do next?". Int J Urol. 2022 Feb;29(2):177-179. doi: 10.1111/iju.14729. Epub 2021 Oct 19.
2. Komai Y, Nakajima K, Saito K, Tomioka Y, Masuda H, Ogawa A, Yonese J, Kobayashi E, Ito M. Development of a new two-arm transurethral surgical system for en bloc resection of bladder tumor-A preclinical study. J Endourol. 2022 Nov 2. doi: 10.1089/end.2021.0917. Online ahead of print
3. Miki J, Yamasaki T, Komai Y, Kanno T, Ohba K, Misawa T; Jikei-Kyoto-Osaka-Nagasaki-Ganken Group (J-KONG Group). Intra- and post-operative management of pancreatic injury during laparoscopic nephrectomy. Int J Urol. 2022 Aug;29(8):905-907. doi: 10.1111/iju.14899. Epub 2022 Apr 19.
4. Fukata K, Akiyoshi T, Numao N, Komai Y, Mukai T, Hiyoshi Y, Yamaguchi T, Nagasaki T, Konishi T, Fukunaga Y. Robotic-assisted laparoscopic surgery for synchronous primary rectal and prostate cancer: Initial case series. Asian J Endosc Surg. 2022 Jul;15(3):678-682. doi: 10.1111/ases.13048. Epub 2022 Mar 13

Renal cell cancer

5. Fujiwara R, Yuasa T, Yamamoto S, Fujiwara M, Takemura K, Urasaki T, Oki R, Komai Y, Oguchi T, Numao N, Yonese J. Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab. Nutr Cancer. 2022 Nov 30:1-8. doi: 10.1080/01635581.2022.2152061
6. Hamada K, Fujiwara R, Takemura K, Komai Y, Oguchi T, Numao N, Yamamoto S,Yonese J, Yuasa T. Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma. Int J Urol. 2022 Oct;29(10):1181-1187.
7. Fujiwara R, Komai Y, Oguchi T, Numao N, Yamamoto S, Yonese J, Yuasa T. Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma. Cancer Diagn Progn. 2022 Jan 3;2(1):25-30. doi: 10.21873/cdp.10072. eCollection 2022 Jan-Feb.PMID: 35399998 
8. Yoshitomi KK, Komai Y, Yamamoto T, Fukagawa E, Hamada K, Yoneoka Y, Fujiwara M, Fujiwara R, Oguchi T, Numao N, Yuasa T, Yamamoto S, Fukui I, Yonese J. Improving accuracy, reliability, and efficiency of the RENAL nephrometry score with 3D reconstructed virtual imaging. Urology. 2022 Jan 27:S0090-4295(22)00073-5.
9. Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee JL, Li H, Agarwal N, Alva AS, Hansen AR, Basappa NS, Szabados B, Powles T, Tran B, Hocking CM, Beuselinck B, Yuasa T, Choueiri TK, Heng DYC. Characterization of Patients with Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-Line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J Urol. 2022 Dec 27:101097JU0000000000003132. doi: 10.1097/JU.0000000000003132. Online ahead of print.
10. Navani V, Ernst M, Wells JC, Yuasa T, Takemura K, Donskov F, Basappa NS, Schmidt A, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, Powles T, McKay RR, Weickhardt A, Suarez C, Kapoor A, Lee JL, Choueiri TK, Heng DYC. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2022 Jun 1;5(6):e2216379. doi: 10.1001/jamanetworkopen.2022.16379.PMID: 35687336

Prostate cancer

11. Fukagawa E, Yuasa T, Inamura K, Hamada K, Fujiwara M, Komai Y, Yonese J. De novo large-cell neuroendocrine carcinoma of the prostate: A case report and literature review. IJU Case Rep 2022 Aug 30;5(6):505-510. doi: 10.1002/iju5.12527. eCollection 2022 Nov.
12. Fujiwara M, Fujiwara R, Oguchi T, Komai Y, Numao N, Yamamoto S, Yonese J, Yuasa T. Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy. Anticancer Res. 2022 Apr;42(4):2123-2130. doi: 10.21873/anticanres.15694
13. Fujiwara M, Numao N, Yamamoto S, Ishikawa Y, Fujiwara R, Oguchi T, Komai Y, Matsuoka Y, Yuasa T, Yonese J. Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy. Prostate. 2022 Jun;82(8):904-910. doi: 10.1002/pros.24334. 
14. Sasamura K, Soyano T, Kozuka T, Yuasa T, Yamamoto S, Yonese J, Oguchi M, Yoshimura R, Yoshioka Y. Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study. Jpn J Clin Oncol. 2022 Feb 5;52(2):170-178. doi: 10.1093/jjco/hyab167.
15. Yokomizo A, Yonese J, Egawa S, Fukuhara H, Uemura H, Nishimura K, Nagata M, Saito A, Lee T, Yamaguchi S, Nonomura N. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan. Int J Clin Oncol. 2022 Feb;27(2):418-426. doi: 10.1007/s10147-021-02070-z. Epub 2021 Nov 15.
16. Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T, Ishiyama H. Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer. Sci Rep. 2022 Jun 30;12(1):11023. doi: 10.1038/s41598-022-15028-6.
17. Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T, Ishiyama H. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Radiat Oncol. 2022 Apr 11;17(1):71. doi: 10.1186/s13014-022-02046-x.

Urothelial cancer

18. Oki R, Urasaki T, Ueki A, Inamura K, Komai Y, Takahashi S, Yonese J, Yuasa T. A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome. IJU Case Rep, 2022https://doi.org/10.1002/iju5.12542
19. Fujiwara M, Yokoyama M, Toide M, Fujiwara R, Tanaka H, Oguchi T, Komai Y, Yoshida S, Matsuoka Y, Numao N, Yamamoto S, Fukui I, Yonese J, Fujii Y. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study. Jpn J Clin Oncol.2022 Dec 15:hyac190. doi: 10.1093/jjco/hyac190. Online ahead of print.
20. Fujiwara M, Fujiwara R, Urasaki T, Oguchi T, Komai Y, Numao N, Yamamoto S, Yonese J, Yuasa T. Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer. Anticancer Res. 2022 Apr;42(4):2045-2051. doi: 10.21873/anticanres.15685.
21. Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, Rosenberg JE, Petrylak DP, Matsangou M, Wu C, Campbell M, Yamashiro M. Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med. 2022 Sep 2. doi: 10.1002/cam4.5165. Online ahead of print.

Others

22. Nakayama I, Shinozaki E, Kawachi H, Sasaki T, Yunokawa M, Tomomatsu J, Yuasa T, Kitazono S, Kobayashi K, Hayakawa K, Ueki A, Takahashi S, Yamaguchi K. Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice. Cancer Med. 2022 Dec 26. doi: 10.1002/cam4.5569. Online ahead of print.

Review

23. Yuasa T, Urasaki T, Oki R. Recent Advances in Medical Therapy for Urological Cancers. Front Oncol. 2022 Apr 4;12:746922. doi: 10.3389/fonc.2022.746922. eCollection 2022.PMID: 35444946 
24. Fujiwara R, Kageyama S, Yuasa T. Developments in personalized therapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2022 May 11:1-9. doi: 10.1080/14737140.2022.2075347. Online ahead of print.PMID: 35531636

Editorial comment

25. Yuasa T. Editorial comment to Biomarkers in Genitourinary Cancers: Volume II. Front Oncol. 2022 https://doi.org/10.3389/fonc.2022.1048736
26. Yuasa T. Editorial comment to A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer. Int J Urol. 2022 Sep 20;5(6):524. doi: 10.1002/iju5.12538. eCollection 2022 Nov
27. Yuasa T. Editorial comment to Clinicopathological features of adrenal malignancies: Analysis of hospital-based cancer registry data in Japan. Int J Urol. 2022 Nov;29(11):1338. 
28. Yuasa T. Editorial Comment from Dr Yuasa to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma. Int J Urol. 2022 Jul;29(7):740. doi: 10.1111/iju.14920. 
29. Yuasa T. Editorial Comment to Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: A report of a rare case. IJU Case Rep. 2022 Mar 8;5(3):156. doi: 10.1002/iju5.12428. eCollection 2022 May.PMID: 35509790 
30. Yuasa T. Editorial Comment to Testicular metastasis from urothelial carcinoma of the bladder. IJU Case Rep 2021 Dec 8;5(2):83-84. doi: 10.1002/iju5.12407. eCollection 2022 Mar.
31. Yuasa T. Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer. Int J Urol. 2022 Jan;29(1):33. doi: 10.1111/iju.14725.

Operation procedures

1. Komai Y, Yamasaki T, Kanno T, Ohba K, Miki J; Jikei-Kyoto-Osaka-Nagasaki-Ganken Group (J-KONG Group). Management of major venous bleeding during minimally invasive pelvic surgery: A proposed protocol for "What should we do next?". Int J Urol. 2021 Oct 19. (in press).
2. Kanno T, Yamasaki T, Komai Y, Ohba K, Miki J; Jikei-Kyoto-Osaka-Nagasaki-Ganken Group (J-KONG Group). Management of venous bleeding during laparoscopic renal surgery: Experiences in the usefulness of soft coagulation and TachoSil. Int J Urol. 2021 Sep;28(9):976-977.

Renal cell cancer

3. Fujiwara R, Takemura K, Fujiwara M, Yuasa T, Yasuoka S, Komai Y, Numao N, Yamamoto S, Yonese J. Modified Glasgow prognostic score as a predictor of prognosis in metastatic renal cell carcinoma treated with nivolumab. Clin Genitourinary Cancer 2021 Apr;19(2):e78-e83. 
4. Fujiwara R, Komai Y, Oguchi T, Numao N, Yamamoto S, Yonese J, Yuasa T. Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma. Cancer Diag Prog (in press).
5. Yamamoto T, Gulanbar A, Hayashi K, Kohno A, Komai Y, Yonese J, Matsueda K, Inamura K. Is hypervascular papillary renal cell carcinoma present? Abdom Radiol (NY). 2021 Apr;46(4):1687-1693.
6. Yasuoka S, Fujiwara M, Yuasa T, Fujisaki J, Komai Y, Numao N, Yamamoto S, Yonese J. Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy: a case report. IJU Case Report 2021 Mar 10;4(3):136-138.
7. Wells JC, Dudani S, Gan CL, Stukalin I, Azad AA, Liow E, Donskov F, Yuasa T, Pal SK, De Velasco G, Hansen AR, Beuselinck B, Kollmannsberger CK, Powles T, McGregor BA, Duh MS, Huynh L, Heng DYC. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. Clin Genitourin Cancer. 2021 Mar 17:S1558-7673(21)00069-0.
8. Araujo DV, Wells JC, Hansen AR, Dizman N, Pal SK, Beuselinck B, Donskov F, Gan CL, Yan F, Tran B, Kollmannsberger CK, de Velasco G, Yuasa T, Reaume MN, Ernst DS, Powles T, Bjarnason GA, Choueiri TK, Heng DYC, Dudani S.J. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. Geriatr Oncol. 2021 Mar 2:S1879-4068(21)00046-1.
9. Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee JL, Hansen A, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, Kroeger N, Kanesvaran R, Reaume MN, Canil C, Choueiri TK, Heng DYC. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Netw Open. 2021 Jan 4;4(1):e2021869.
10. Komai Y. Editorial Comment to Histological and radiological evaluation of thermal denaturation depth using soft coagulation during partial nephrectomy in living pigs. Int J Urol. 2021 Dec;28(12):1280-1281.
11. Yuasa T, Editorial comment to Expression of Tertiary Lymphoid Structure in Deferred Cytoreductive Nephrectomy of Metastatic Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab. IJU Case Report. 2021 Aug 17;4(6):358-359.
12. Yuasa T. Editorial comment on: Effect of improved systemic therapy on patient survival in metastatic non-clear cell renal cell. Int J Urol2021 May;28(5):607.
13. Yuasa T. Editorial Comment to Cystic partially differentiated nephroblastoma in a 74-year-old patient.IJU Case Rep. 2021 Aug 25;4(6):395. 

Urothelial cancer　（Bladder cancer, Renal pelvic cancer, Ureterial cancer）

14. Fujiwara M, Yuasa T, Urasaki T, Komai Y, Fujiwara R, Numao N, Yamamoto S, Yonese J. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan. Cancer Rep (Hoboken). 2021 May 2:e1398. 
15. Kijima T, Yamamoto H, Saito K, Kusuhara S, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Sakai Y, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2 2021 Mar;70(3):657-665.
16. Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Association between the occurrence and spectrum of immune-related adverse events and efficacy of pembrolizumab in Asian patients with advanced urothelial cancer: Multicenter retrospective analyses and systematic literature review Clin Genitourinary Cancer 2021 Jun;19(3):208-216.e1.
17. Yuasa T. Editorial Comment to Testicular metastasis from urothelial carcinoma of the bladder. IJU Case Reports. (in press).
18. Yuasa T. Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer. Int J Urol. 2021 Sep;28(9):975.

Prostate cancer

19. Fukagawa E, Yamamoto S, Ohde S, Yoshitomi KK, Hamada K, Yoneoka Y, Fujiwara M, Fujiwara R, Oguchi T, Komai Y, Numao N, Yuasa T, Fukui I, Yonese J. External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer. Int J Clin Oncol. 2021 Sep;26(9):1736-1744. 
20. Fujiwara M, Yuasa T, Yasuoka S, Komai Y, Ogichi T, Fujiwara R, Numao N, Yamamoto S, Yonese J. Serum and hematological responses to cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 2021 Sep;88(3):525-531. 
21. Fujiwara M, Yuasa T, Komai Y, Fujiwara R, Oguchi T, Numao N, Yamamoto S, Yonese J. Switching prostate cancer patients from GnRH antagonist to long-acting LH-RH agonist for androgen deprivation: Reducing hospital visits during the coronavirus pandemic. Cancer Diag Prog 2021. (in press).
22. Amori G, Sugawara E, Shigematsu Y, Akiya M, Kunieda J, Yuasa T, Yamamoto S, Yonese J, Takeuchi K, Inamura K. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer and Prostatic Diseases 2021 Sep;24(3):767-774.
23. Yokomizo A, Yonese J, Egawa S, Fukuhara H, Uemura H, Nishimura K, Nagata M, Saito A, Lee T, Yamaguchi S, Nonomura N. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan. Int J Clin Oncol. 2021 Nov 15. (in press).
24. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Nishimura K, Yonese J, Hashine K, Masumori N, Arai G, Saito S, Shinohara M, Shimizu N, Yamauchi A, Satoh T, Tochigi T, Kobayashi M, Fujimoto H, Kakimoto KI, Fukui I, Tsukamoto T, Nozaki M, Karasawa K, Hasumi M, Ohtani M, Ishiyama H, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Naito S, Yamanaka H; National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators. Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial. Cancer Med. 2021 May;10(10):3240-3248.
25. Minagawa T, Oguchi T, Saitou T, Fukazawa A, Hashida I, Koiwai K, Iijima K, Kato H, Ogawa T, Ishizuka O. Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial. Int J Urol. 2021 Apr;28(4):432-438.
26. Shimoyachi N, Yoshioka Y, Sasamura K, Yonese J, Yamamoto S, Yuasa T, Soyano T, Kozuka T, Oguchi M. Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After Prostatectomy. Adv Radiat Oncol. 2021 Jul 13;6(6):100753.
27. Une M, Takemura K, Inamura K, Fukushima H, Ito M, Kobayashi S, Yuasa T, Yonese J, Board PG, Koga F. Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel. Cancers (Basel). 2021 Nov 8;13(21):5587.
28. Sasamura K, Soyano T, Kozuka T, Yuasa T, Yamamoto S, Yonese J, Oguchi M, Yoshimura R, Yoshioka Y. Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study. Jpn J Clin Oncol. 2021 Oct 23:hyab167. (in press).
29. Yamamoto S. Editorial Comment to Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy. Int J Urol. 2021 Oct;28(10):1045-1046.
30. Yuasa T. Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer. Int J Urol. 2021 Oct 6. (in press).

Germ cell cancer

31. Fujiwara M, Tanaka H, Yuasa T, Komai Y, Ogichi T, Fujiwara R, Numao N, Yamamoto S, Fujii Y, Fukui I, Yonese J. First-line combination chemotherapy with etoposide, ifosfamide, and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice. Int J Urol 2021 Apr 30;11:681997. 
32. Fujiwara M, Hayashi T, Takeda H, Yuasa T, Komai Y, Numao N, Yamamoto S, Fukui I, Kouno T, Yonese J. Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer. Clin Genitourin Cancer. 2021 Feb;19(1):e6-e11.
33. Yoshitomi KK, Numao N, Umino Y, Fujiwara M, Fujiwara R, Oguchi T, Komai Y, Yuasa T, Yamamoto S, Yonese J. The utility of diffusion-weighted whole-body imaging with background body signal suppression in detecting metastatic lesion of germ cell carcinoma. IJU Case Rep. 2021 Jun 16;4(5):285-288. 

Others

34. Urasaki T, Nishizawa M, Yoshida A, Tomomatsu J, Yuasa T, Yonese J, Takahashi S. Severe pseudomembranous keratoconjunctivitis with deterioration of eyesight induced by immune checkpoint inhibitors. Immunotherapy. 2021 Nov 23. (in press).
35. Urasaki T, Ono M, Mochizuki T, Takeda K, Nishizawa A, Fukagawa E, Fujiwara M, Komai Y, Kitano S, Yuasa T, Yonese J, Takahashi S. A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome. Frontiers in Oncology. 2021 Apr 30;11:681997. 
36. Urasaki T, Nakano K, Tomomatsu J, Komai Y, Yuasa T, Yamashita K, Takazawa Y, Yamamoto S, Yonese J, Takahashi S. Adult Genitourinary Sarcoma: the era of optional chemotherapeutic agents for soft tissue sarcoma. Int J Urol 2021 Jan;28(1):91-97. 
37. Ohmoto A, Shigematsu Y, Fukuda N, Wang X, Urasaki T, Hayashi N, Sato Y, Nakano K, Yunokawa M, Ono M, Komai Y, Numao N, Yuasa T, Yonese J, Tomomatsu J, Inamura K, Takahashi S. Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. Endocr J. 2021 Jun 26. doi: 10.1507/endocrj.EJ21-0277. Online ahead of print. (in press)
38. Fujiwara Y, Ohmoto A, Fukuda N, Wang X, Urasaki T, Hayashi N, Sato Y, Nakano K, Yunokawa M, Ono M, Tomomatsu J, Yuasa T, Yonese J, Takahashi S. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy. Endocr J. 2021 Jun 28;68(6):671-681.
39. Yuasa T. Editorial comment to the article, titled, “A case of adenocarcinoma of the rete testis with durable response to cisplatin-based chemotherapy. IJU Case Report 2021 Jun 21;4(5):271-272. 

前立腺がん

1. Fujiwara, M., Komai, Y., Yuasa, T., Numao, N., Yamamoto, S., Fukui, I., Yonese, J. Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high. IJU Case Rep., 3 (2): 62-64, 2020
2. Fujiwara M, Yuasa T, Komai Y, Numao N, Yamamoto S, Fukui I, Yonese J. Efficacy, prognostic factors, and safety profile of enzalutamide for castration-resistant prostate cancer: a retrospective single-center analysis in Japan. Targeted Oncol 2020 (in press).
3. Ito, K., Kobayashi, M., Komiyama, M., Naito, S., Nishimura, K., Yonese, J., Hashine, K., Saito, S., Arai, G., Shinohara, M., Masumori, N., Shimizu, N., Satoh, T., Yamauchi, A., Tochigi, T., Takezawa, Y., Fujimoto, H., Yokomizo, A., Kakimoto, K. I., Fukui, I., Karasawa, K., Tsukamoto, T., Nozaki, M., Hasumi, M., Ishiyama, H., Ohtani, M., Kuwahara, M., Harada, M., Ohashi, Y., Kotake, T., Kakizoe, T., Suzuki, K., Yamanaka, H. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial. Cancer, 126 (17): 3961-3971, 2020
4. Yamamoto, T., Ishizuka, O., Oike, H., Shiozaki, M., Haba, T., Oguchi, T., Iijima, K., Kato, H. Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Prostate international, 8 (1): 27-33, 2020

尿路上皮がん（膀胱がん・腎盂がん・尿管がん）

5. Numao, N., Fujiwara, R., Uehara, S., Yasuoka, S., Fujiwara, M., Komai, Y., Yuasa, T., Yamamoto, S., Fukui, I., Yonese, J. Intraoperative only versus extended duration use of antimicrobial prophylaxis for infectious complications in radical cystectomy with intestinal urinary diversion. Urol. Int.: in press, 2020
6. Ogawa, M., Yamamoto, S., Inoue, T., Numao, N., Yuasa, T., Masuda, H., Fukui, I., Yonese, J. Phase II study of second-line chemotherapy with paclitaxel, gemcitabine, and cisplatin for advanced urothelial carcinoma. Anticancer Res., 40 (3): 1613-1618, 2020
7. Yamamoto, S., Kageyama, Y., Fujii, Y., Aizawa, T., Urakami, S., Fukui, I. Randomized study of postoperative single intravesical instillation with pirarubicin and mitomycin C for low-risk bladder cancer. Anticancer Res.: in press, 2020
8. Fukushima, H., Kijima, T., Fukuda, S., Moriyama, S., Uehara, S., Yasuda, Y., Tanaka, H., Yoshida, S., Yokoyama, M., Matsuoka, Y., Saito, K., Matsubara , N., Numao, N., Sakai, Y., T., Y., Masuda, H., Yonese, J., Kageyama, Y., Fujii, Y. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab in advanced urothelial cancer patients. Cancer Med.: in press, 2020
9. Kijima, T., Fukushima, H., Kusuhara, S., Tanaka, H., Yoshida, S., Yokoyama, M., Ishioka, J., Matsuoka, Y., Numao, N., Sakai, Y., Saito, K., Matsubara, N., Yuasa, T., Masuda, H., Yonese, J., Kageyama, Y., Fujii, Y. Association between the occurrence and spectrum of immune-related adverse events and efficacy of pembrolizumab in Asian patients with advanced urothelial cancer: Multicenter retrospective analyses and systematic literature review. Clin. Genitourin. Cancer: in press, 2020
10. Kijima, T., Yamamoto, H., Saito, K., Kusuhara, H., Yoshida, S., Yokoyama, M., Matsuoka, Y., Numao, N., Sakai, Y., Matsubara, N., Yuasa ,T., Masuda, H., Yonese, J., Kageyama, Y., Fujii, Y. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunology, Immunotherapy: in press, 2020
11. Yuasa, T. Editorial comment to Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. IJU Case Rep., 3 (1): 27-28, 2020
12. Yuasa T. Editorial comment on: Bowel movement conditions predict therapeutic effects of pembrolizumab on urothelial cancer patients. Int J Urol 2020 (in press).

腎がん

13. Fujiwara, R., Inamura, K., Yuasa, T., Numao, N., Yamamoto, S., Masuda, H., Kawauchi, A., Takeuchi, K., Yonese, J. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer. Int. J. Clin. Oncol., 25 (1): 151-157, 2020
14. Fujiwara R, Takemura K, Fujiwara M, Yuasa T, Yasuoka S, Komai Y, Numao N, Yamamoto S, Yonese J. Modified Glasgow prognostic score as a predictor of prognosis in metastatic renal cell carcinoma treated with nivolumab. Clin Genitourinary Cancer 2020 (in press).
15. Yasuoka S, Yuasa T, Fujiwara R, Komai Y, Numao N, Yamamoto S, Kondo Y, Yonese J. Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer. Anticancer Res 2020 (in press).
16. Takemura, K., Yuasa, T., Fujiwara, R., Ito, M., Suzuki, H., Yonese, J., Koga, F. Prognostic significance of the controlling nutritional status (CONUT) score in patients with advanced renal cell carcinoma treated with nivolumab after failure of prior tyrosine kinase inhibitors. J. Urol.: in press, 2020
17. Takemura, K., Yuasa, T., Inamura, K., Amori, G., Koga, F., Board, P. G., Yonese, J. Impact of serum γ-glutamyltransferase on overall survival in patients with metastatic renal cell carcinoma in the era of targeted therapy. Target. Oncol., 15 (3): 347-356, 2020
18. Hinata, N., Yonese, J., Masui, S., Nakai, Y., Shirotake, S., Tatsugami, K., Inamoto, T., Nozawa, M., Ueda, K., Etsunaga, T., Osawa, T., Uemura, M., Kimura, G., Numakura, K., Yamana, K., Miyake, H., Fukasawa, S., Ochi, K., Kaneko, H., Uemura, H. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data. Int. J. Clin. Oncol.: in press, 2020
19. Kubota S, Yoshida T, Kageyama S, Isono T, Yuasa T, Yonese J, Kushima R, Kawauchi A, Chano T. A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma. World J Surg Oncol. 2020 Oct 22;18(1):270. doi: 10.1186/s12957-020-02046-9.
20. Yamamoto T, Gulanbar A, Hayashi K, Kohno A, Komai Y, Yonese J, Matsueda K, Inamura K. Is hypervascular papillary renal cell carcinoma present? Abdom Radiol (NY). 2020 Oct 12.
21. Izumi, K., Saito, K., Nakayama, T., Fukuda, S., Fukushima, H., Uehara, S., Koga, F., Yonese, J., Kageyama, Y., Fujii, Y. Contact with renal sinus is associated with poor prognosis in surgically treated pT1 clear cell renal cell carcinoma. Int. J. Urol., 27 (8): 657-662, 2020
22. Bhindi, B., Graham, J., Wells, J. C., Bakouny, Z., Donskov, F., Fraccon, A., Pasini, F., Lee, J. L., Basappa, N. S., Hansen, A., Kollmannsberger, C. K., Kanesvaran, R., Yuasa, T., Ernst, D. S., Srinivas, S., Rini, B. I., Bowman, I., Pal, S. K., Choueiri, T. K., Heng, D. Y. C. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur. Urol.: in press, 2020
23. Donskov, F., Xie, W., Overby, A., Wells, J. C., Fraccon, A. P., Sacco, C. S., Porta, C., Stukalin, I., Lee, J. L., Koutsoukos, K., Yuasa, T., Davis, I. D., Pezaro, C., Kanesvaran, R., Bjarnason, G. A., Sim, H. W., Rathi, N., Kollmannsberger, C. K., Canil, C. M., Choueiri , T. K., Heng, D. Y. C. Synchronous versus metachronous metastatic disease: Impact of time to metastasis on patient outcome-results from theIinternational Metastatic Renal Cell Carcinoma Database Consortium. Eur. Urol. Oncol.: in press, 2020
24. Yuasa, T. A novel classification for local recurrence after surgical removal of renal cell cancer. Editorial comment on: Local Recurrence Following Resection of Intermediate- to High-Risk Non-Metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. Ann. Transl .Med.: in press, 2020
25. Yuasa, T. Editorial comment on: Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma. IJU Case Rep.: in press, 2020
26. Yuasa, T. Editorial comment on: prognostic implication of body mass index on survival outcomes in surgically-treated non-metastatic renal cell carcinoma: A single institutional, retrospective analysis of a large cohort. Ann. Surg. Oncol., 27 (7): 2137-2138, 2020
27. Yuasa T. Editorial comment on: Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma. IJU Case Reports. 2020, 3: 218.
28. Yuasa T. Editorial comment on: Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma: a case report. IJU Case Reports. (in press).

胚細胞がん　（精巣がん）

29. Fujiwara, M., Hayashi, T., Takeda, H., Yuasa, T., Komai, Y., Numao, N., Yamamoto, S., Fukui, I., Kouno, T., Yonese, J. Cisplatin, gemcitabine, and paclitaxel as a salvage second-line therapy for metastatic germ-cell cancer.Clin. Genitourin. Cancer: in press, 2020
30. Sano, Y., Fujiwara, M., Yuasa, T., Komai, Y., Yamamoto, T., Kohno, A., Nakao, M., Inamura, K., Yonese, J. Testicular seminoma with a progressing pulmonary nodule and mediastinal lymphadenopathy without retroperitoneal metastasis. IJU Case Rep.: in press, 2020

その他

31. Fujiwara, R., Numao, N., Ishikawa, Y., Inoue, T., Ogawa, M., Masuda, H., Yuasa, T., Yamamoto, S., Fukui, I., Yonese, J. Incidence and predictors of deep vein thrombosis in patients with elevated serum D-dimer prior to surgery for urologic malignancy. Urol. Int., 104 (1-2): 1-6, 2020.
32. Yamamoto, S. Editorial Comment to Rare gastrointestinal stromal tumor in an ileal conduit detected by recurrent massive bleeding from the stoma. IJU Case Rep.: in press, 2020
33. Urasaki T, Nakano K, Tomomatsu J, Komai Y, Yuasa T, Yamashita K, Takazawa Y, Yamamoto S, Yonese J, Takahashi S. Adult Genitourinary Sarcoma: the era of optional chemotherapeutic agents for soft tissue sarcoma. Int J Urol 2020 (in press).
34. Yuasa, T. Editorial comment from Dr Yuasa to Clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan. Int. J. Urol., 27 (2): 163, 2020

前立腺がん

1. Uemura H, Uemura H, Nagamori S, Wakumoto Y, Kimura G, Kikukawa H, Yokomizo A, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Akagawa T, Matsubara N. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases. Int J Clin Oncol. 2019 May;24(5):557-566.
2. Yasuoka S, Yuasa T, Ogawa M, Komai Y, Numao N, Yamamoto S, Kondo Y, Yonese J. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan. Anticancer Res. 2019 Oct;39(10):5803-5809. doi: 10.21873/anticanres.13784
3. Yuasa T. Editorial Comment to Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. Int J Urol. 2019 May 12. doi: 10.1111/iju.14018.

尿路上皮癌

4. Yasuoka S, Yuasa T, Nishimura N, Ogawa M, Komai Y, Numao N, Yamamoto S, Kondo Y, Yonese J. Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer. Anticancer Res. 2019 Jul;39(7):3887-3892.
5. Yuasa T. Editorial comment to Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. IJU Case Reports. 2019 (in press).
6. Toide M, Yokoyama M, Fujiwara M, Kijima T, Saito K, Fujii Y. Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cystectomy. Int J Urol. 2019 Oct;26(10):1010-1012.
7. Kobayashi M, Tanaka H, Tateishi U, Numao N, Yonese J, Ito M, Koga F, Fukushima H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. Int J Urol. 2019 Aug;26(8):820-826.

腎がん

8. Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. Jpn J Clin Oncol. 2019 Jun 1;49(6):506-514.
9. Fujiwara R, Inamura K, Yuasa T, Numao N, Yamamoto S, Masuda H, Kawauchi A, Takeuchi K, Yonese J. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer. Int J Clin Oncol. 2019 Sep 14. doi: 10.1007/s10147-019-01542-7
10. Isono T, Chano T, Yoshida T, Makino A, Ishida S, Suzaki M, Kageyama S, Kawauchi A, Yonese J, Yuasa T. ADP-ribosylation factor-like 4C is a predictive biomarker of poor prognosis in patients with renal cell carcinoma. Am J Cancer Res 2019;9:415-423.
11. Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, Choueiri TK, Heng DYC. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30609-8. doi: 10.1016/j.eururo.2019.07.048.
12. Inamura K, Amori G, Yuasa T, Yamamoto S, Yonese J, Ishikawa Y. Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma. Cancer Management and Research 2019, 11:7021-7030
13. Stukalin I, Wells JC, Graham J, Yuasa T, Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, Hansen AR, Bjarnason GA, Srinivas S, Wood LA, Alva AS, Kanesvaran R, Fu SYF, Davis ID, Choueiri TK, Heng DYC.　Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.　Curr Oncol. 2019 Apr;26(2):e175-e179. doi: 10.3747/co.26.4595.

胚細胞腫瘍

14. Yuasa T. Editorial comment to Syndrome of inappropriate antidiuretic hormone secretion as a side effect of chemotherapy for testicular cancer: report of a case. Int J Urol. 2019 (in press).
15. Yuasa T. Editorial Comment to Comparison of the predictive value among inflammation-based scoring systems for bleomycin pulmonary toxicity in patients with germ cell tumors. Int J Urol. 2019 May 26. doi: 10.1111/iju.14030.

その他

16. Fujiwara R, Numao N, Ishikawa Y, Inoue T, Ogawa M, Masuda H, Yuasa T, Yamamoto S, Fukui I, Yonese J. Incidence and Predictors of Deep Vein Thrombosis in Patients with Elevated Serum D-Dimer Prior to Surgery for Urologic Malignancy. Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502660.
17. Yamamoto T, Koizumi M, Kohno A, Numao N, Inamura K. A case report on 111 In chloride bone marrow scintigraphy in management of adrenal myelolipoma. Medicine (Baltimore). 2019 Feb;98(8):e14625.
18. Araki S, Kijima T, Waseda Y, Komai Y, Nakanishi Y, Uehara S, Yasuda Y, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Nakano Y, Yoshimoto T, Uchida T, Fujii Y. Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. Int J Urol. 2019 Feb;26(2):273-277.
19. Ken Imaizumi, Yuichiro Tsukada, Yoshinobu Komai, Shogo Nomura, Koji Ikeda, Yuji Nishizawa, Takeshi Sasaki, Akinobu Taketomi, Masaaki Ito. Prediction of Urinary Retention After Surgery for Rectal Cancer Using Voiding Efficiency in the 24 H Following Foley Catheter Removal. Int J Colorectal Dis, 34 (8), 1431-1443, 2019
20. Yuasa T. Editorial comment to The clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan. Int J Urol. 2019 (in press).

前立腺がん

1. Ito K, Saito S, Yorozu A, Kojima S, Kikuchi T, Higashide S, Aoki M, Koga H, Satoh T, Ohashi T, Nakamura K, Katayama N, Tanaka N, Nakano M, Shigematsu N, Dokiya T, Fukushima M; J-POPS Investigators. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival.Int J Clin Oncol. 2018 Jun 22. doi: 10.1007/s10147-018-1309-0.
2. Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura HPhase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. Int J Clin Oncol. 2018 Feb;23(1):173-180. doi: 10.1007/s10147-017-1176-0. Epub 2017 Aug 2.
3. Ishioka J, Matsuoka Y, Uehara S, Yasuda Y, Kijima T, Yoshida S, Yokoyama M, Saito K, Kihara K, Numao N, Kimura T, Kudo K, Kumazawa I, Fujii Y. Computer-aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm. BJU Int. 2018 Sep;122(3):411-417. doi: 10.1111/bju.14397. Epub 2018 Jun 7.

尿路上皮がん

4. Yuasa T, Urakami S, Yonese J. Recent advances in medical therapy for metastatic urothelial cancer. Int J Clin Oncol.2018 Mar 20. doi: 10.1007/s10147-018-1260-0.
5. Baba M, Kageyama S, Yoshida T, Fujiwara R, Kim CJ, Takimoto K, Nagasawa M, Soga H, Nagatani Y, Nishikawa Z, Kawauchi A. Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer. Int J Clin Oncol. 2018 May 14. doi: 10.1007/s10147-018-1292-5.

腎がん

6. Komai Y, Gotohda N, Matsubara N, Takeda H, Yuasa T, Inoue M, Yamamoto S, Yonese J. Preliminary kidney parenchymal ligation using Endoloop® ligatures-A simple method to achieve a trifecta in laparoscopic partial nephrectomy without hilar clamping for polar complex tumors. Urology.2018 Aug 29. pii: S0090-4295(18)30907-5. doi: 10.1016/j.urology.2018.08.023.
7. Yuasa T. Editorial comment to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with tyrosine kinase inhibitors as a first-line therapy for metastatic renal cell carcinoma. Int J Urol2018 Jun;25(6):604-605
8. Isono T, Chano T, Yoshida T, Kageyama S, Kawauchi A, Yonese J, Yuasa T. Abundance of TRAIL attenuated by HIF2α and c-FLIP affects malignancy in renal cell carcinomas. Oncotarget.2018 May 1;9(33):23091-23101. doi: 10.18632/oncotarget.25214. eCollection 2018 May 1.
9. Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC.　Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium.　Cancer.2018 Oct 11
10. Yoshida T, Kageyama S, Isono T, Yuasa T, Kushima R, Kawauchi A, Chano T. Superoxide dismutase 2 expression can predict prognosis of renal cell carcinoma patients. Cancer Biomark.2018 Jun 6.

その他

11. Araki S, Kijima T, Waseda Y, Komai Y, Nakanishi Y, Uehara S, Yasuda Y, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Nakano Y, Yoshimoto T, Uchida T, Fujii Y. Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. Int J Urol. 2018 Nov 22. doi: 10.1111/iju.13864.

前立腺がん

1. Koizumi M, Motegi K, Koyama M, Terauchi T, Yuasa T, Yonese J. Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups. Ann Nucl Med. 2017 Aug;31(7):521-528.
2. Kozuka T, Nakano M, Hashimoto M, Gomi K, Murofushi KN, Sumi M, Yonese J, Oguchi M. Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer. Jpn J Radiol. 2017 May;35(5):269-278.
3. Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer. Int J Clin Oncol. 2018 Feb;23(1):173-180.
4. Kim CS, Choi YD, Lee SE, Lee HM, Ueda T, Yonese J, Fukagai T, Chiong E, Lau W, Abhyankar S, Theeuwes A, Tombal B, Beer TM, Kimura G. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer. Medicine (Baltimore). 2017 Jul;96(27):e7223.
5. Suzuki H, Inoue Y, Fujimoto H, Yonese J, Tanabe K, Fukasawa S, Inoue T, Saito S, Ueno M, Otaka A. Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate pancer: multicenter Phase IIb clinical trial. Jpn J Clin Oncol. 2017 Mar 1;47(3):283. doi: 10.1093/jjco/hyw177
6. Sakai Y, Komai Y, Saito N, Ito M, Sakuraba M.　Analysis of a Surgical Treatment for Persistent Urorectal Fistulas after Radical Cancer Surgery: A Comparison of Prostate Cancer and Rectal Cancer.　Urol Int. 2017;99(1):56-62.

尿路上皮がん

7. Inamura K, Kobayashi M, Nagano H, Sugiura Y, Ogawa M, Masuda H, Yonese J, Ishikawa Y. A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder. Hum Pathol. 2017 Nov;69:96-100.
8. Komai Y.　Editorial Comment to Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma.　Int J Urol. 2017 May;24(5):366.

腎がん

9. Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin Oncol. 2017 Jul 1;47(7):639-646.
10. Yuasa T, Masuda H, Yamamoto S, Numao N, Yonese J. Biomarkers to predict prognosis and response to checkpoint inhibitors. Int J Clin Oncol. 2017 Aug;22(4):629-634.
11. Uehara S, Yuasa T, Fujisaki J, Fujii Y, Yamamoto S, Masuda H, Fukui I, Yonese J. A case of gastric metastasis from renal cell cancer during the sequential targeted therapy. Int Cancer Conf J. 2017 July:6(3) 114-7
12. Yasuda Y, Saito K, Yuasa T, Uehara S, Kawamura N, Yokoyama M, Ishioka J, Matsuoka Y, Yamamoto S, Okuno T, Yonese J, Kihara K, Fujii Y. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 2017 Jul 21. doi: 10.1007/s10147-017-1166-2
13. Tanaka H, Fujii Y, Tanaka H, Ishioka J, Matsuoka Y, Saito K, Uehara S, Numao N, Yuasa T, Yamamoto S, Masuda H, Yonese J, Kihara K. Stepwise algorithm using computed tomography and magnetic resonance imaging for diagnosis of fat-poor angiomyolipoma in small renal masses: Development and external validation. Int J Urol. 2017 Jul;24(7):511-517.
14. Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DY. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol. 2017 Jun;71(6):970-978

その他

15. Muto M, Inamura K, Ozawa N, Endo T, Masuda H, Yonese J, Ishikawa Y. Skene's gland adenocarcinoma with intestinal differentiation: A case report and literature review. Pathol Int. 2017 Nov;67(11):575-579. 5.
16. Li J, Motoi N, Kanda H, Sugiura Y, Nagano H, Yonese J, Okumura S, Matsumoto S, Machinami R, Ishikawa Y. A newly emerged osteosarcomatous dedifferentiation of liposarcoma in lung metastasis - a potential diagnostic pitfall. Pathol Int. 2017 Jan;67(1):50-52.
17. Yoshida S, Ito M, Tatokoro M, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Fujii Y, Kihara K.　Multitask Imaging Monitor for Surgical Navigation: Combination of Touchless Interface and Head-Mounted Display.　Urol Int. 2017;98(4):486-488.
18. Noguchi K, Nishizawa Y, Komai Y, Sakai Y, Kobayasi A, Ito M, Saito N.　Efficacy of an additional flap operation in bladder-preserving surgery with radical prostatectomy and cystourethral anastomosis for rectal cancer involving the prostate.　Surg Today. 2017 Sep;47(9):1119-1128
19. Yuasa T. Editorial comment to Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy. Int J Urol 2017 Jun;24(6):453.

前立腺がん

1. Yamasaki M, Yuasa T, Yamamoto S, Hayashi T, Ogawa M, Sakura M, Masuda H, Fukui I, Yonese J. Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer. Anticancer Res. 2016 Jan;36(1):361-5.
2. Sano M, Yamamoto S, Uehara S, Yuasa T, Masuda H, Fukui I, Yonese J. Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report. Mol Clin Oncol. 2016 Sep;5(3):208-210.
3. Kimura G, Yonese J, Fukagai T, Kamba T, Nishimura K, Nozawa M, Mansbach H, Theeuwes A, Beer TM, Tombal B, Ueda T. Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial. Int J Urol. 2016 May;23(5):395-403. doi: 10.1111/iju.13072.
4. Suzuki H, Inoue Y, Fujimoto H, Yonese J, Tanabe K, Fukasawa S, Inoue T, Saito S, Ueno M, Otaka A. Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial. Jpn J Clin Oncol. 2016 Feb;46(2):152-62. doi: 10.1093/jjco/hyv181
5. Suzuki H, Inoue Y, Fujimoto H, Yonese J, Tanabe K, Fukasawa S, Inoue T, Saito S, Ueno M, Otaka A. Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate pancer: multicenter Phase IIb clinical trial. Jpn J Clin Oncol. 2016 Dec 4. [Epub ahead of print]
6. Matsuoka Y, Numao N, Saito K, Tanaka H, Kumagai J, Yoshida S, Ishioka J, Koga F, Masuda H, Kawakami S, Fujii Y, Kihara K. Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy. BJU Int. 2016 Jan;117(1):94-101.

腎がん

7. Isono T, Chano T, Yoshida T, Kageyama S, Kawauchi A, Suzaki M, Yuasa T: Hydroxyl-HIF2-alpha is potential therapeutic target for renal cell carcinomas. Am J Cancer Res 2016;6(10):2263-2276.
8. Isono T, Chano T, Yonese J, Yuasa T. Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas. Sci Rep. 2016 May 9;6:25669. doi: 10.1038/srep25669.
9. Kawamura N, Yokoyama M, Fujii Y, Ishioka J, Numao N, Matsuoka Y, Saito K, Arisawa C, Okuno T, Noro A, Morimoto S, Kihara K. Recovery of renal function after radical nephrectomy and risk factors for postoperative severe renal impairment: A Japanese multicenter longitudinal study. Int J Urol. 2016 Mar;23(3):219-23.
10. Yamasaki M, Shin T, Sato R, Hirai K, Kan T, Fujinami H, Mori K, Sumino Y, Nomura T, Sato F, Masuda H, Yonese J, Mimata H. Pfannenstiel laparoendoscopic reduced-port radical nephrectomy. Asian J Endosc Surg. 2016 Aug;9(3):222-5. doi: 10.1111/ases.12290
11. Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DY. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30687-X.
12. Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, Bjarnason GA, Lee JL, Sim HW, Sliwczynsk A, Ptak-Chmielewska A, Teter Z, Beuselinck B, Wood LA, Yuasa T, Pezaro C, Rini BI, Szczylik C, Choueiri TK, Heng DY. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer. 2016;65:102-108.
13. Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol. 2016 Sep 6. pii: JCO667311. [Epub ahead of print]

尿路上皮がん　(膀胱がんなど)

14. Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T, Yamamoto S, Masuda H, Koizumi M, Kohno A, Fukui I, Yonese J, Fujii Y, Kihara K. Clinical Value of F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management. Urol Int. 2016;96(1):65-72.
15. Yuasa T. Editorial Comment to Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.　Int J Urol. 2016 Jul 31. doi: 10.1111/iju.13178. [Epub ahead of print]

尿膜管がん　その他

16. Hayashi T, Yuasa T, Uehara S, Inoue Y, Yamamoto S, Masuda H, Fujii Y, Fukui I, Yonese J. Clinical outcome of urachal cancer in Japanese patients. Int J Clin Oncol. 2016 Feb;21(1):133-8.
17. Li J, Motoi N, Kanda H, Sugiura Y, Nagano H, Yonese J, Okumura S, Matsumoto S, Machinami R, Ishikawa Y. A newly emerged osteosarcomatous dedifferentiation of liposarcoma in lung metastasis - a potential diagnostic pitfall. Pathol Int. 2016 Nov 23. doi: 10.1111/pin.12482. [Epub ahead of print]
18. Nakayama T, Numao N, Yoshida S, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K. A novel interactive educational system in the operating room--the IE system. BMC Med Educ. 2016 Feb 2;16:44.
19. Ito M, Kihara K, Yoshida S, Tatokoro M, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Fujii Y. Patient's Self-monitoring of Transurethral Surgical Images Using a Head-mounted Display. Urol Case Rep. 2015 Jan 6;3(2):27-9.

骨転移

20. Yamasaki M, Yuasa T, Uehara S, Fujii Y, Yamamoto S, Masuda H, Fukui I, Yonese J. Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab. Int J Clin Oncol. 2016 Jul 11. [Epub ahead of print]
21. Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N, Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open. 2016 Mar 16;1(2):e000037.

尿膜管がん

1. Hayashi T, Yuasa T, Uehara S, Inoue Y, Yamamoto S, Masuda H, Fujii Y, Fukui I, Yonese J. Clinical outcome of urachal cancer in Japanese patients. Int J Clin Oncol. 2015 (in press).

精巣がん

2. Yuasa T, Inoshita N, Tanaka H, Urakami S, Yamamoto S, Fujii Y, Masuda H, Fukui I, Ishikawa Y, Yonese J. Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era. Int J Clin Oncol. (in press).

前立腺がん

3. Yamasaki M, Yuasa T, Yamamoto S, Hayashi T, Ogawa M, Sakura M, Masuda H, Fukui I, Yonese J. Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer. Anticancer Research (in press).
4. Uehara S, Yuasa T, Fujii Y, Yano A, Yamamoto S, Masuda H, Fukui I, Yonese J. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer. BMC Res Notes. 2015 Aug 5;8:335.
5. Yasuda Y, Fujii Y, Yuasa T, Yamamoto S, Yonese J, Fukui I. Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade? Int J Urol. 2015 Jan;22(1):132-3.
6. Yamamoto S, Masuda H, Urakami S, Fujii Y, Sakamoto K, Kozuka T, Oguchi M, Fukui I, Yonese J.　Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy. Urology. 2015 Feb;85(2):407-13.

尿路上皮がん

7. Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T, Yamamoto S, Masuda H, Koizumi M, Kohno A, Fukui I, Yonese J, Fujii Y, Kihara K. Clinical Value of F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management. Urol Int. 2015 Jun 4. [Epub ahead of print]
8. Urakami S, Yuasa T, Yamamoto S, Sakura M, Tanaka H, Hayashi T, Uehara S, Inoue Y, Fujii Y, Masuda H, Fukui I, Yonese J. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery. Int J Clin Oncol. 2015 May 8. [Epub ahead of print]
9. Ishioka J, Saito K, Kijima T, Nakanishi Y, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Sakura M, Yonese J, Morimoto S, Noro A, Tsujii T, Kitahara S, Gotoh S, Higashi Y, Kihara K. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2015 May;115(5):705-12.
10. Miyazaki J, Nishiyama H, Fujimoto H, Ohyama C, Koie T, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T. Laparoscopic versus open nephroureterectomy in muscle-invasive upper tract urothelial carcinoma: Subanalysis of the multi-institutional national database of the Japanese Urological Association. J Endourol. 2015 Dec 16. [Epub ahead of print]
11. Inokuchi J, Naito S, Fujimoto H, Hara T, Sakura M, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C; Cancer Registration Committee of the Japanese Urological Association. Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association. Int J Urol. 2015 Dec 14. doi: 10.1111/iju.13031. [Epub ahead of print]
12. Hara T, Fujimoto H, Sakura M, Inokuchi J, Nishiyama H, Miyazaki J, Ohyama C, Koie T, Kikuchi E, Hinotsu S; Cancer Registration Committee of the Japanese Urological Association. Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association. Int J Urol. 2015 Nov;22(11):1013-20.
13. Miyazaki J, Nishiyama H, Fujimoto H, Ohyama C, Koie T, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T; Cancer Registration Committee of the Japanese Urological Association. Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multi-institutional national database. Int J Urol. 2015 Nov;22(11):1023-7.

腎がん

14. Yuasa T, Inoshita N, Saiura A, Yamamoto S, Urakami S, Masuda H, Fujii Y, Fukui I, Ishikawa Y, Yonese J. Clinical outcome of patients with pancreatic metastases from renal cell cancer. BMC Cancer. 2015 15:46.
15. Yuasa T. Editorial comment on: p21-activated kinase 1 predicts recurrence and survival of patients with non-metastatic clear‐cell renal cell carcinoma. Int J Urol. 2015 May;22(5):453-4.
16. Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015 Mar;16(3):293-300.
17. Fay AP, Xie WL, Lee LC, Harshman LC, Bjarnason GA, Knox SE, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwa N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DYC. Characteristics of Long-term and Short-term Survivors of Metastatic Renal Cell Carcinoma Treated with Targeted Therapies: Results from the International mRCC Database Consortium. Clinical Genitourinary Cancer 2015 Apr;13(2):150-5.
18. Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI. Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer 2015 Apr;13(2):e79-85.

精巣がん

1. Tanaka H, Yuasa T, Fujii Y, Sakura M, Kitsukawa S, Urakami S, Yamamoto S, Masuda H, Fukui I, Yonese J. First-line combination chemotherapy with cisplatin, etoposide, and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era. Chemotherapy 2014;59(6):441-6..

前立腺がん

1. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Kitsukawa S, Masuda H, Ishikawa Y, Kozuka T, Oguchi M, Kohno A, Fukui I. Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution. Int J Clin Oncol. 2014 Dec;19(6):1085-91. doi: 10.1007/s10147-013-0654-2. Epub 2013 Dec 19.
2. Yamamoto S, Fujii Y, Masuda H, Urakami S, Saito K, Kozuka T, Oguchi M, Fukui I, Yonese J. Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer. Qual Life Res. 2014 Jun;23(5):1641-50. doi: 10.1007/s11136-013-0603-6. Epub 2013 Dec 13.
3. Mashima T, Soma-Nagae T, Migita T, Kinoshita R, Iwamoto A, Yuasa T, Yonese J, Ishikawa Y, Seimiya H. TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression. Cancer Res. 2014 Jun 24. pii: canres.3718.2013. [Epub ahead of print]
4. Yasuda Y, Fujii Y, Yuasa T, Yamamoto S, Yonese J, Fukui I. Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade? Int J Urol. 2014 Sep 22.
5. Fujii Y, Yamamoto S, Yonese J, Masuda H, Urakami S, Kitsukawa S, Sakura M, Yuasa T, Kihara K, Fukui I. The Processus Vaginalis Transection Method to Prevent Postradical Prostatectomy Inguinal Hernia: Long-term Results. Urology. 2014 Jan;83(1):247-52.
6. Suzuki S, Chino A, Fukui I, Hayashi T, Kozuka T, Suganuma T, Kishihara T, Tamegai Y, Fujisaki J, Oguchi M, Yonese J, Igarashi M. Successful use of endoscopic argon plasma coagulation for hemorrhagic radiation cystitis: a case report. Jpn J Clin Oncol.2014 Jul;44(7):692-5. doi: 10.1093/jjco/hyu066. Epub 2014 May 16.
7. Matsubara N, Uemura H, Fukui I, Niwakawa M, Yamaguchi A, Iizuka K, Akaza H. Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistant prostate cancer. Cancer Sci. 2014 Oct;105(10):1313-20.

尿路上皮癌

1. Ishioka J, Masuda H, Kijima T, Tatokoro M, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Yonese J, Kageyama Y, Noro A, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Kihara K. Bimodal pattern of the impact of body mass index on cancer-specific survival of upper urinary tract urothelial carcinoma patients. Anticancer Res. 2014 Oct;34(10):5683-8.
2. Fukushima H, Saito K, Ishioka J, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Yonese J, Kamata S, Nagahama K, Noro A, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Higashi Y, Kihara K. Equivalent survival and improved preservation of renal function after distal ureterectomy compared with nephroureterectomy in patients with urothelial carcinoma of the distal ureter: a propensity score-matched multicenter study. Int J Urol. 2014 Nov;21(11):1098-104. doi: 10.1111/iju.12554. Epub 2014 Jul 14.
3. Ishioka J, Saito K, Kijima T, Nakanishi Y, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Sakura M, Yonese J, Morimoto S, Noro A, Tsujii1 T, Kitahara S, Gotoh S, Higashi Y, Kihara K. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2014 Feb 25. doi: 10.1111/bju.12707. [Epub ahead of print]
4. Izumiyama-Shimomura N, Nakamura K, Aida J, Ishikawa N, Kuroiwa M, Hiraishi N, Fujiwara M, Ishikawa Y, Inoshita N, Yonese J, Matsuura M, Poon SS, Arai T, Takubo K. Short telomeres and chromosome instability prior to histologic malignant progression and cytogenetic aneuploidy in papillary urothelial neoplasms. Urol Oncol. 2014 Feb;32(2):135-45. doi: 10.1016/j.urolonc.2012.12.005. Epub 2013 Mar 17.

腎がん

1. Yuasa T, Urakami S. Decreased incidence of skeletal-related events in mRCC. Nature Reviews in Urology. 2014 Apr;11(4):193-4.
2. Yuasa T. Editorial Comment to Efficacies of traditional and alternative sunitinib treatment schedules in patients with metastatic renal cell carcinoma in a Japanese population. Int J Urol 2014 (in press).
3. Yuasa T. Editorial Comment to Localized non-conventional renal cell carcinoma: Prediction of clinical outcome according to histology. Int J Urol. 2014;21(4):364-5.
4. Isono T, Chano T, Kitamura A, Yuasa T. Glucose Deprivation Induces G2/M Transition-Arrest and Cell Death in N-GlcNAc2-Modified Protein-Producing Renal Carcinoma Cells. PLoS One. 2014 May 5;9(5):e96168. doi:
5. Tsuchiya N, Yuasa T, Maita S, Narita S, Inoue T, Numakura K, Saito M, Satoh S, Yonese J, Habuchi T. Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma. BMC Urology 2014, 14:26 (11 March 2014)
6. Fay AP, Xie WL, Lee LC, Harshman LC, Bjarnason GA, Knox SE, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwa N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DYC. Characteristics of Long-term and Short-term Survivors of Metastatic Renal Cell Carcinoma Treated with Targeted Therapies: Results from the International mRCC Database Consortium. Clinical Genitourinary Cancer (in press).
7. Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI. Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer (in press).
8. Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK. Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014 Jun 12. pii: S0302-2838(14)00494-1.
9. Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK. First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer. 2014 Oct;12(5):335-40.
10. Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014 Jan;25(1):149-54.
11. Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer. 2014 Apr 15;110(8):1917-22.
12. Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK. The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol. 2014 Apr;65(4):723-30.
13. Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamis A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. Eur Urol. 2014 Jun;65(6):1086-92.

腎がん

1. Yasuda Y, Yuasa T, Yamamoto S, Urakami S, Ito M, Sukegawa G, Kitsukawa S, Fujii Y, Yonese J, Fukui I. Evaluation of the RENAL nephrometry scoring system in adopting nephron-sparing surgery for cT1 renal cancer Urologia Int 2013;90(2):179-83.
2. Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol. 2013 Oct;18(5):877-83.
3. Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 2013 Oct;18(5):884-9.
4. Yuasa T, Kitsukawa S, Sukegawa G, Yamamoto S, Kudo K, Miyazawa K, Kozuka T, Harada S, Yonese J. Early onset recall pneumonitis during targeted therapy with sunitinib.BMC Cancer. 2013; 13:3.
5. Kroeger N, Xie W,Lee JL,Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DYC. Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium (IMDC) Criteria. Cancer 2013;119(16):2999-3006.
6. Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamis A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. Eur Urol. (in press).

尿路上皮がん

1. Urakami S, Fujii Y, Yamamoto S, Yuasa T, Kitsukawa S, Sakura M, Yano A, Saito K, Masuda H, Yonese J, Fukui I. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. Urol Oncol. 2013 (in press).

前立腺がん

1. Yamamoto, S. Editorial comment to high percent tumor volume predicts biochemical recurrence after radical prostatectomy in pathological stage T3a prostate cancer with a negative surgical margin Int. J. Urol.: in press, 2013
2. Yamamoto, S., Fujii, Y., Masuda, H., Urakami, S., Saito, K., Kozuka, T., Oguchi, M., Fukui, I., Yonese, J. Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer Qual. Life. Res.: in press, 2013
3. Yamamoto, S., Kawakami, S., Yonese, J., Fujii, Y., Urakami, S., Kitsukawa, S., Masuda, H., Ishikawa, Y., Kozuka, T., Oguchi, M., Kohno, A., Fukui, I. Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution Int. J. Clin. Oncol.: in press, 2013
4. Masuda, H. Editorial comment to longitudinal leak point pressure measurements in rats using a modified port a cath system Int. J. Urol., 20 (12): 1242, 2013
5. Masuda H, Kagawa M, Kawakami S, Numao N, Matsuoka Y, Yokoyama M, Yamamoto S, Yonese J, Fukui I, Kihara K.Body mass index influences prostate cancer risk at biopsy in Japanese men. Int J Urol. 2013 Jul;20(7):701-7.

前立腺がん

1. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A, Fukui I. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy. Jpn J Clin Oncol. 2012 Jun;42(6):541-7.
2. Numao N, Kawakami S, Sakura M, Yoshida S, Koga F, Saito K, Masuda H, Fujii Y, Yamamoto S, Yonese J, Ishikawa Y, Fukui I, Kihara K. Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy. BJU Int. 2012 Mar;109(5):665-71.
3. Masuda H, Kagawa M, Kawakami S, Numao N, Matsuoka Y, Yokoyama M, Yamamoto S, Yonese J, Fukui I, Kihara K. Body mass index influences prostate cancer risk at biopsy in Japanese men. Int J Urol. 2012 Nov 27. doi: 10.1111/iju.12023.
4. Masuda H, Kawakami S, Sakura M, Fujii Y, Koga F, Saito K, Numao N, Yonese J, Fukui I, Kihara K. Performance of prostate-specific antigen mass in estimation of prostate volume in Japanese men with benign prostate hyperplasia. Int J Urol. 2012 Oct;19(10):929-35.
5. Nakanishi Y, Masuda H, Kawakami S, Sakura M, Fujii Y, Saito K, Koga F, Ito M, Yonese J, Fukui I, Kihara K. A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia. Asian J Androl. 2012 Sep;14(5):703-7. doi: 10.1038/aja.2012.31.
6. Fukushima H, Masuda H, Kawakami S, Ito M, Sakura M, Numao N, Koga F, Saito K, Fujii Y, Yamamoto S, Yonese J, Fukui I, Kihara K. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL. Urology. 2012 Jun;79(6):1329-34.
7. Komai Y, Kawakami S, Numao N, Fujii Y, Saito K, Kubo Y, Koga F, Kumagai J, Yamamoto S, Yonese J, Ishikawa Y, Fukui I, Kihara K. Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer. BJU Int. 2012 Dec;110(11 Pt B):E564-9.
8. Narita S, Tsuchiya N, Yuasa T, Maita S, Obara T, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Habuchi T. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int J Clin Oncol 2012 Jun;17(3):204-11

腎がん

1. Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol. 2012 Sep 11. [Epub ahead of print]
2. Yasuda Y, Yuasa T, Yamamoto S, Urakami S, Ito M, Sukegawa G, Kitsukawa S, Fujii Y, Yonese J, Fukui I. Evaluation of the RENAL nephrometry scoring system in adopting nephron-sparing surgery for cT1 renal cancer Urologia Int(in press)
3. Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol.2012 Aug 11. [Epub ahead of print]
4. Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, Yamamoto S, Yonese J, Fukui I, Ishikawa Y. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012 Jan;36(1):35-42. doi: 10.1097/PAS.0b013e3182293ec3.
5. Sugawara S, Togashi Y, Kuroda N, Sakata S, Hatano S, Asaka R, Yuasa T, Yonese J, Kitagawa M, Mano H, Ishikawa Y, Takeuchi K. Identification of ALK fusions in renal cancer: Large-scale immunohistochemical screening by intercalated antibody-enhanced polymer method. Cancer2012;118:4427-36.
6. Yuasa T, Tsuchiya N, Horikawa Y, Narita S, Inoue T, Urakami S, Yamamoto S, Yonese J, Takahashi S, Hatake K, Fukui I. Habuchi T. Clinical Efficacy and Prognostic Factors for Overall Survival in Japanese Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. BJU int.2012 May;109(9):1349-54.
7. Yuasa T, Fujii Y, Takahashi S, Fukui I, Yonese J. Molecular targeted therapies for patients with metastatic renal cell cancer. Translational Med2012.
8. Maita S, Yuasa T, Tsuchiya N, Mitobe M, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, Maekawa T, Habuchi T. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer2012;130:677-84.

尿路上皮がん

1. Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, Kitsukawa S, Okubo Y, Yamamoto S, Yonese J, Fukui I. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. BJU Int. 2012 Nov;110(10):1478-84.

骨転移

1. Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J. Denosumab: a new option in the treatment of bone metastases from urological cancers. OncoTargets and Therapy.2012: 5; 221-9.

1. Hayasaka K, Koyama M, Fukui I. FDG PET imaging in a patient with primary seminoma of the prostate. Clin Nucl Med. 2011;36:593-4.
   
2. Numao N, Kawakami S, Sakura M, Yoshida S, Koga F, Saito K, Masuda H, Fujii Y, Yamamoto S, Yonese J, Ishikawa Y, Fukui I, Kihara K. Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy. BJU Int. 2012;109:665-71.
   
3. Koga F, Fujii Y, Masuda H, Numao N, Yokoyama M, Ishioka JI, Saito K, Kawakami S, Kihara K. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches. BJU Int. 2012 Jan 30.
   
4. Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, Yamamoto S, Yonese J, Fukui I, Ishikawa Y. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012 Jan;36:35-42.
   
5. Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 2011;10:4291-9.
   
6. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One. 2011;6(11):e27616.
   
7. Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N, Sakura M, Kawakami S, Kihara K. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 2011 Dec;41(12):1373-9.
   
8. Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L, Kihara K. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer. 2011 Sep 30. doi: 10.1002/ijc.26475.
   
9. Numao N, Kawakami S, Sakura M, Yoshida S, Koga F, Saito K, Masuda H, Fujii Y, Yamamoto S, Yonese J, Ishikawa Y, Fukui I, Kihara K. Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy.BJU Int. 2012 Mar;109(5):665-71.
   
10. Koga F, Kihara K, Yoshida S, Yokoyama M, Saito K, Masuda H, Fujii Y, Kawakami S. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int. 2011 Aug 19. doi:
    
11. Tanaka H, Yoshida S, Fujii Y, Ishii C, Tanaka H, Koga F, Saito K, Masuda H, Kawakami S, Kihara K. Diffusion-weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma. Int J Urol. 2011 Oct;18(10):727-30. 10.1111/j.1442-2042.2011.02824.x. Epub 2011 Aug 4.
    
12. Kobayashi S, Koga F, Yoshida S, Masuda H, Ishii C, Tanaka H, Komai Y, Yokoyama M, Saito K, Fujii Y, Kawakami S, Kihara K. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol. 2011 Oct;21(10):2178-86.
    
13. Yokoyama M, Fujii Y, Iimura Y, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Longitudinal change in renal function after radical nephrectomy in Japanese patients with renal cortical tumors. J Urol. 2011 Jun;185(6):2066-71.
    
14. Komai Y, Fujii Y, Iimura Y, Tatokoro M, Saito K, Otsuka Y, Koga F, Arisawa C, Kawakami S, Okuno T, Tsujii T, Kageyama Y, Morimoto S, Toma T, Higashi Y, Fukui I, Kihara K. Young age as favorable prognostic factor for cancer-specific survival in localized renal cell carcinoma.Urology. 2011 Apr;77(4):842-7.
    
15. Yoshida S, Masuda H, Ishii C, Tanaka H, Fujii Y, Kawakami S, Kihara K. Usefulness of diffusion-weighted MRI in diagnosis of upper urinary tract cancer. AJR Am J Roentgenol. 2011 Jan;196(1):110-6.
    
16. Sakura M, Kawakami S, Ishioka J, Fujii Y, Yamamoto S, Iwai A, Numao N, Saito K, Koga F, Masuda H, Kumagai J, Yonese J, Fukui I, Kihara K. A novel repeat biopsy nomogram based on three-dimensional extended biopsy. Urology. 2011 Apr;77(4):915-20.
    
17. Tatokoro M, Fujii Y, Kawakami S, Saito K, Koga F, Matsuoka Y, Iimura Y, Masuda H, Kihara K. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 2011 Jan;102(1):137-43. doi: 10.1111/j.1349-7006.2010.01756.x.
    
18. Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I. Biomarkers to Predict Response to Sunitinib Therapy and Prognosis in Metastatic Renal Cell Cancer. Cancer Science;102:1949-57.
    
19. Yuasa T, Fujii Y, Takahashi S, Fukui I, Yonese J. Molecular targeted therapies for patients with metastatic renal cell cancer. Translational Med (in press).
    
20. Maita S, Yuasa T, Tsuchiya N, Mitobe M, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, Maekawa T, Habuchi T. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer 2012;130:677-84.
    
21. Yuasa T, Tsuchiya N, Horikawa Y, Narita S, Inoue T, Urakami S, Yamamoto S, Yonese J, Takahashi S, Hatake K, Fukui I. Habuchi T. Clinical Efficacy and Prognostic Factors for Overall Survival in Japanese Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. BJU int. (in press).
    
22. Yuasa T, Urakami S, Yamamoto S, Yonese J, Takahashi S, Hatake K, Fukui I. Treatment Outcome and Prognostic Factors of the Patients with Renal Cell Cancer Bone Metastasis. Clin Exp Metastasis 2011; 28: 405-11.
    
23. Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikawa Y, Fukui I. Tumor Size is a Potential Predictor of the Response to Tyrosine Kinase Inhibitors in Renal Cell Cancer. Urology 2011; 77: 831-5.
    
24. Sugawara S, Togashi Y, Kuroda N, Sakata S, Hatano S, Asaka R, Yuasa T, Yonese J, Kitagawa M, Mano H, Ishikawa Y, Takeuchi K. Identification of ALK fusions in renal cancer: Large-scale immunohistochemical screening by intercalated antibody-enhanced polymer method. Cancer (in press).
    
25. Urakami S, Yonese J, Yamamoto S, Yuasa T, Kitsukawa S, Numao N, Kubo Y, Ito M, Sukegawa G, Yasuda Y, Ishikawa Y, Fukui I. Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml. Urol Int. 2011;87:175-81.
    
26. Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, Kitsukawa S, Urakami S, Yuasa T, Yamamoto S, Yonese J, Fukui I. Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel. Urology. 2011;78:1131-5.
    
27. Numakura K, Tsuchiya N, Yuasa T, Saito M, Obara T, Tsuruta H, Narita S, Horikawa Y, Satoh S, Habuchi T. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol 2011;16:577-80.
    
28. Narita S, Tsuchiya N, Yuasa T, Maita S, Obara T, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Habuchi T. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int J Clin Oncol 2011 (in press).
    
29. Saito M, Tsuchiya N, Maita S, Numakura K, Obara T, Tsuruta H, Kumazawa T, Inoue T, Narita S, Horikawa Y, Yuasa T, Satoh S, Habuchi T. What Is the Most Preferred Wound Site for Laparoscopic Donor Nephrectomy?: A Questionnaire Assessment. J Laparoendosc Adv Surg Tech A 2011; 21: 511-5.

1. Takeshita H, Yonese J, Fukui I. Successful long-term [corrected] remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic non-seminomatous [corrected] germ cell tumor: an additional report to Int J Clin Oncol 2007; 12:485-487. Int J Clin Oncol. 2010 Oct;15(5):528-9.
2. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Tsukamoto T, Okubo Y, Kijima T, Ishikawa Y, Fukui I. Feasibility of antegrade radical prostatectomy for clinically locally advanced prostate cancer: a comparative study with clinically localized disease. Int J Urol. 2010 Aug;17(8):720-5. 
3. Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology. 2010 May;75(5):1131-7.
4. Fujii Y, Yamamoto S, Yonese J, Kawakami S, Okubo Y, Suyama T, Komai Y, Kijima T, Fukui I. A novel technique to prevent postradical retropubic prostatectomy inguinal hernia: the processus vaginalis transection method. Urology. 2010 Mar;75(3):713-7.
5. Inoue S, Shiina H, Sumura M, Urakami S, Matsubara A, Igawa M. Impact of a novel, extended approach of perineal radical prostatectomy on surgical margins in localized prostate cancer. BJU Int. 2010 Jul;106(1):44-8.
6. Kodaira M, Takahashi S, Takeuchi K, Yuasa T, Saotome T, Yonese J, Fukui I, Hatake K. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma in Japanese patients. Ann Oncol. 2010; 21, 1563-5.
7. Ma Z, Tsuchiya N, Yuasa T, Huang M, Obara T, Narita S, Horikawa Y, Tsuruta H, Saito M, Satoh S, Ogawa O, Habuchi T. Clinical Significance of Polymorphism and Expression of Chromogranin A and Endothelin-1 in Prostate Cancer. J Urol. 2010; 184, 1182-8.

1. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Tsukamoto T, Ohkubo Y, Komai Y, Ishikawa Y, Fukui I. Risk stratification of high-grade prostate cancer treated with antegrade radical prostatectomy with intended wide resection. Jpn J Clin Oncol. 2009 Jun;39(6):387-93.
2. Takeshita H, Kawakami S, Fukui I Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy. Int J Urol. 2009 Mar;16(3):337-8.
3. Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M, Nakamura T, Fukui I. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009 Feb 15;15(4):1170-6. 11.
4. Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009 Mar;181(3):1004-12; discussion 1012.
5. Inoue S, Shiina H, Hiraoka T, Mitsui Y, Sumura M, Urakami S, Igawa M. Retrospective analysis of the distance between the neurovascular bundle and prostate cancer foci in radical prostatectomy specimens: its clinical implication in nerve-sparing surgery. BJU Int. 2009 Oct;104(8):1085-90.
6. Inoue S, Shiina H, Hiraoka T, Wake K, Sumura M, Honda S, Urakami S, Igawa M, Usui T. Five-year longitudinal effect of radical perineal prostatectomy on health-related quality of life in Japanese men, using general and disease-specific measures. BJU Int. 2009 Oct;104(8):1077-84.
7. Kikuno N, Kawamoto K, Hirata H, Vejdani K, Kawakami K, Fandel T, Nunes L, Urakami S, Shiina H, Igawa M, Tanagho E, Dahiya R. Nerve growth factor combined with vascular endothelial growth factor enhances regeneration of bladder acellular matrix graft in spinal cord injury-induced neurogenic rat bladder. BJU Int. 2009 May;103(10):1424-8.
8. Wang W, Yuasa T, Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T. The novel tumor-suppressor Mel-18 in prostate cancer:  its functional polymorphism, expression, and clinical significance. Int J Cancer. 2009; 125: 2836-43.
9. Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N, Habuchi T, Maekawa T, Kimura S. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother. 2009; 58: 493-502.
10. Yuasa T. Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. Int J Urol. 2009;16: 731-2.
11. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H. A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety. Jpn J Clin Oncol. 2009 Nov 7.
12. Tsuchiya N, Narita S, Kumazawa T, Inoue T, Ma Z, Tsuruta H, Saito M, Horikawa Y, Yuasa T, Satoh S, Ogawa O, Habuchi T.Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. Oncol Rep. 2009; 22: 493-9.
13. Kumazawa T, Tsuchiya N, Saito M, Inoue T, Narita S, Horikawa Y, Yuasa T, Satoh S, Kato T, Nanjyo H, Habuchi T. Cystoprostatectomy as a treatment of prostate cancer involving the bladder neck. Urol Int. 2009; 83: 141-5.

1. Numao N, Kawakami S, Yonese J, Koga F, Saito K, Fujii Y, Ishikawa Y, Fukui I, Kihara K. Three-dimensional 26-core biopsy-based patient selection criteria for nerve-sparing radical prostatectomy. Int J Urol. 2008 Dec;15(12):1061-6.
2. Kawakami S, Koga F, Fujii Y, Saito K, Yamamoto S, Tatokoro M, Yonese J, Kageyama Y, Fukui I, Kihara K. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. Int J Urol. 2008 Dec;15(12):1055-60.
3. Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int. 2009 Mar;103(5):620-4.
4. Tatokoro M, Kawakami S, Yonese J, Fujii Y, Okubo Y, Yamamoto S, Takeshita H, Komai Y, Ishikawa Y, Fukui I. Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. Int J Urol. 2008 Sep;15(9):851-3.
5. Tatokoro M, Fujii Y, Kawakami S, Fukui N, Komai Y, Saito K, Koga F, Morimoto S, Fukui I, Kihara K. Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases. Int J Urol. 2008 Sep;15(9):848-50.
6. Komai Y, Fujii Y, Okubo Y, Yamamoto S, Kawakami S, Yonese J, Fukui I. Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy. Int J Urol. 2008 Oct;15(11):971-5.
7. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Tsukamoto T, Ohkubo Y, Komai Y, Ishikawa Y, Fukui I. Prognostic significance of cancer volume involving seminal vesicles in patients with pT3bpN0 prostate cancer. Urology. 2008 Dec;72(6):1224-8.
8. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Ohkubo Y, Suyama T, Komai Y, Kijima T, Ishikawa Y, Fukui I. Lymphovascular invasion is an independent predictor of prostate-specific antigen failure after radical prostatectomy in patients with pT3aN0 prostate cancer. Int J Urol. 2008 Oct;15(10):895-9.
9. Fujii Y, Komai Y, Saito K, Iimura Y, Yonese J, Kawakami S, Ishikawa Y, Kumagai J, Kihara K, Fukui I. Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients. Urology. 2008 Sep;72(3):598-602. Epub 2008 Jul 23.
10. Kijima T, Fujii Y, Suyama T, Okubo Y, Yonese J, Fukui I. Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. Int J Urol. 2008 Jun;15(6):546-7.
11. Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K, Fujii Y, Yonese J, Masuda H, Kihara K, Fukui I. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol. 2008 Sep;54(3):601-11.
12. Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. BJU Int. 2008 May;101(9):1096-100.
13. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Majid S, Igawa M, Dahiya R. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer. 2008 Aug 1;123(3):552-60.
14. Urakami S, Shiina H, Sumura M, Honda S, Wake K, Hiraoka T, Inoue S, Ishikawa N, Igawa M. Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade. Int Urol Nephrol. 2008;40(2):365-8. 7.
15. Narita N, Yuasa T, Tsuchiya N, Kumazawa T, Narita S, Inoue T, Ma Z, Saito M, Horikawa Y, Satoh S, Ogawa O, Habuchi T. A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer. 8: 224, 2008.
16. Wang W, Yuasa T, Tsuchiya N, Maita S, Kumazawa T, Inoue T, Saito M, Ma Z, Obara T, Tsuruta H, Satoh S, Habuchi T. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer. 2008; 15: 943-52.
17. Yuasa T, Tsuchiya N, Kumazawa T, Inoue T, Narita S, Saito M, Horikawa Y, Satoh S, Habuchi T. Characterization of prostate cancer detected at repeat biopsy. BMC Urology 2008; 8: 14.
18. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Narita S, Kumazawa T, Narita S, Horikawa Y, Tsuruta H, Obara T, Saito M, Satoh S, Ogawa O, Habuchi T. Polymorphisms of Fibroblast groth factor receptor 4 have association with the progression of prostate cancer in Japanese population. Int J Cancer2008; 123: 2574-9..
19. Tsuchiya N, Inoue T, Narita S, Kumazawa T, Saito M, Obara T, Tsuruta H, Horikawa Y, Yuasa T, Satoh S, Habuchi T. Drug-related Genetic Polymorphisms affecting Adverse Reactions of MVAC in Patients with Urothelial Cancer. J Urol 2008; 180: 2389-95.
20. Horikawa Y, Nadaoka J, Saito M, Kumazawa T, Inoue T, Yuasa T, Tsuchiya N, Nishiyama H, Ogawa O, Habuchi T. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep. 2008; 20: 49-55.
21. Saito M, Yuasa T, Satoh S, Nanjo H, Tsuchiya N, Habuchi T. Developing multiple lung nodules in a renal transplant recipient with tuberous sclerosis who had undergone bilateral nephrectomy due to renal cell carcinomas. Int J Urol. 2008 15: 257-8.
22. Saito M, Yuasa T, Nanjo H, Tsuchiya N, Satoh S, Habuchi T. A case of testicular angiomyolipoma. Int J Urol. 2008 15: 185-7.
23. Nadaoka J, Horikawa Y, Inoue T, Narita S, Kumazawa T, Saito M, Yuasa T, Satoh S, Nishiyama H, Ogawa, O, Habuchi T, Tsuchiya N.Significance of HIF-1alpha Polymorphisms in Transitional Cell Carcinoma of the Bladder. Int J Cancer 2008 122:1297-302.
24. Narita S, Tsuchiya N, Saito M, Inoue T, Kumazawa T, Yuasa T, Nakamura A, Habuchi T. Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis. Prostate. 2008; 68: 321-35.
25. Saito M, Satoh S, Kagaya H, Tsuruta H, Obara T, Kumazawa T, Inoue T, Inoue K, Miura M, Yuasa T, Komatsuda A, Tsuchiya N, Habuchi T. Thrombotic microangiopathy developing in early stage after renal transplantation with a high trough level of tacrolimus. Clin Exp Nephrol. 2008; 12: 312-5.

1. Takeshita H, Yonese J, Fujii Y, Kawakami S, Komai Y, Ohkubo Y, Yamamoto S, Ishikawa Y, Seto Y, Ohyama S, Fukui I. Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor. Int J Clin Oncol. 2007 Dec;12(6):485-7.
2. Sakura M, Tsujii T, Yamauchi A, Tadokoro M, Tsukamoto T, Kawakami S, Yonese J, Fukui I. Superior vena cava syndrome caused by supraclavicular lymph node metastasis of renal cell carcinoma. Int J Clin Oncol. 2007 Oct;12(5):382-4.
3. Okubo Y, Yonese J, Kawakami S, Yamamoto S, Komai Y, Takeshita H, Ishikawa Y, Fukui I. Obstinate cough as a sole presenting symptom of non-metastatic renal cell carcinoma. Int J Urol. 2007 Sep;14(9):854-5.
4. Kawakami S, Fukui I, Yonese J, Okubo Y, Yamamoto S, Tsukamoto T, Ishikawa Y. Antegrade radical retropubic prostatectomy with preliminary ligation of vascular pedicles in 614 consecutive patients. Jpn J Clin Oncol. 2007 Jul;37(7):528-33.
5. Kawakami S, Yamamoto S, Numao N, Ishikawa Y, Kihara K, Fukui I. Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer. Int J Urol. 2007 Aug;14(8):719-24.
6. Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, Takeshita H, Ishikawa Y, Fukui I. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007 Sep;52(3):696-701.
7. Malkowicz SB, van Poppel H, Mickisch G, Pansadoro V, Thuroff J, Soloway MS, Chang S, Benson M, Fukui I. Muscle-invasive urothelial carcinoma of the bladder. Urology. 2007 Jan;69(1 Suppl):3-16.
8. Numao N, Kawakami S, Yokoyama M, Yonese J, Arisawa C, Ishikawa Y, Ando M, Fukui I, Kihara K. Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy. Eur Urol. 2007 Dec;52(6):1663-8. 33.
9. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z, Majid S, Enokida H, Nakagawa M, Dahiya R. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res. 2007 May 1;13(9):2541-8.
10. Urakami S, Shiina H, Enokida H, Kawamoto K, Kikuno N, Fandel T, Vejdani K, Nunes L, Igawa M, Tanagho EA, Dahiya R. Functional improvement in spinal cord injury-induced neurogenic bladder by bladder augmentation using bladder acellular matrix graft in the rat. World J Urol. 2007 Apr;25(2):207-13.
11. Tanaka Y, Hirata H, Chen Z, Kikuno N, Kawamoto K, Majid S, Tokizane T, Urakami S, Shiina H, Nakajima K, Dhir R, Dahiya R. Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):92-7.
12. Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, Wake K, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol. 2007 May;51(5):1252-8.
13. Kikuno N, Urakami S, Nakamura S, Shiina H, Igawa M. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone. Int J Urol. 2007 Jan;14(1):82-4.
14. Fukuda H, Tsuchiya N, Narita S, Kumazawa T, Horikawa Y, Inoue T, Saito M, Yuasa T, Matsuura S, Satoh S, Ogawa O, Habuchi T. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol Rep. 18:1155-63, 2007.
15. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid ?a multiplicity of anti-cancer action-. Current Medicinal Chemistry 14:2126-35, 2007.
16. Kageyama S, Iwaki H, Inoue H, Isono T, Yuasa T, Nogawa M, Maekawa T, Ueda M, Kajita Y, Ogawa O, Toguchida J, Yoshiki T. A novel tumor-related protein, C7orf24, identified by proteome differential display of bladder urothelial carcinoma. Proteomics Clin Appl 1: 192-9, 2007.
17. Horikawa Y, Kumazawa T, Narita S, Inoue T, Yuasa T, Matsuura S, Nanjo H, Satoh S, Tsuchiya N, Habuchi T. Lymphatic invasion is a prognostic factor for bladder cancer treated with radical cystectomy. Int J Clin Oncol. 12:131-6. 2007
18. Kanzaki M, Kakinuma H, Kumazawa T, Inoue T, Saito M, Narita S, Yuasa T, Tsuchiya N, Habuchi T. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol Rep. 17: 761-7, 2007.

1. Yamamoto S, Yonese J, Kawakami S, Tsukamoto T, Ohkubo Y, Tatokoro M, Fukui I. Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer. Int J Clin Oncol. 2006 Aug;11(4):326-8.
2. Kawakami S, Okuno T, Yonese J, Igari T, Arai G, Fujii Y, Kageyama Y, Fukui I, Kihara K. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol. 2007 Mar;51(3):675-82; discussion 682-3.
3. Tsukamoto T, Yonese J, Ohkubo Y, Fukui I. Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma. Cancer. 2006 Jun 1;106(11):2363-8.
4. Kawakami S, Hyochi N, Yonese J, Yano M, Fujii Y, Kageyama Y, Fukui I, Kihara K. Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. Int J Clin Oncol. 2006 Apr;11(2):127-32.
5. Sakura M, Tsukamoto T, Yonese J, Ishikawa Y, Aoki N, Fukui I. Successful therapy of a malignant phyllodes tumor of the prostate after postoperative local failure. Urology. 2006 Apr;67(4):845.e11-3.
6. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, Kikuno N, Tanaka Y, Majid S, Nakagawa M, Igawa M, Dahiya R. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res. 2006 Dec 1;12(23):6989-97.
7. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42.
8. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24.
9. Okino ST, Pookot D, Li LC, Zhao H, Urakami S, Shiina H, Igawa M, Dahiya R. Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer. Cancer Res. 2006 Aug 1;66(15):7420-8.
10. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16.
11. Hirata H, Hinoda Y, Matsuyama H, Tanaka Y, Okayama N, Suehiro Y, Zhao H, Urakami S, Kawamoto K, Kawakami T, Igawa M, Naito K, Dahiya R. Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochem Biophys Res Commun. 2006 Apr 21;342(4):1058-62.
12. Tanaka Y, Sasaki M, Shiina H, Tokizane T, Deguchi M, Hirata H, Hinoda Y, Okayama N, Suehiro Y, Urakami S, Kawakami T, Kaneuchi M, Pookot D, Igawa M, Okuyama A, Ishii N, Dahiya R. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):238-44.
13. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, Kikuno N, Adachi H, Yoneda T, Kishi H, Shigeno K, Konety BR, Igawa M, Dahiya R. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res. 2006 Jan 15;12(2):383-91.
14. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer. 2006 Jan 1;106(1):79-86.
15. Yuasa T, Tsuchiya N, Narita S, Inoue T, Saito M, Kumazawa T, Horikawa Y, Matsuura S, Satoh S, Nanjo H, Habuchi T. Radical nephroureterectomy as an initial treatment for carcinoma in situ of the upper urinary tract. Urology; 68: 972-5, 2006.
16. Sato K, Yuasa T, Nogawa M, Kimura S, Segawa H, Yokota A, Maekawa T. A third generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer 95: 1354-61, 2006.
17. Kataoka A, Yuasa T, Kageyama S, Tsuchiya N, Habuchi T, Iwaki H, Narita M, Okada Y, Yoshiki T. Measurement of serum ICTP helps ALP and PSA in the diagnosis of bone metastasis of in patients with prostate cancer patients by measurement of serum ICTP in combination with ALP and PSA. Clinical Oncology 18: 480-484, 2006.
18. Horie N, Murata H, Nishigaki T, Segawa H, Yuasa T, Kimura T, Maekawa T, Fushiki S, Kubo T. The third-generation bisphosphonates inhibit tumor proliferation and induce apoptosis in murine osteosarcoma in vitro. Cancer Lett 238: 111-118, 2006.
19. Yuasa T, Yoshida T, Wakabayashi Y, Kataoka A, Narita M, Yoshiki T, Okada Y. Successful treatment of disseminated extragonadal germ cell cancer with intensive conventional chemotherapy after first-line high dose chemotherapy. Int J Clin Oncol 11:60-3, 2006
20. Tsuchiya N, Mishina M, Narita S, Kumazawa T, Inoue T, Horikawa Y, Kakinuma H, Yuasa T, Matsuura S, Satoh S, Ogawa O, Habuchi T. Association of XRCC1 gene polymorphisms with the susceptibility and chromosomal aberration of testicular germ cell tumors. Int J Oncol 28: 1217-23, 2006.

1. Tadokoro M, Yonese J, Tsukamoto T, Okubo Y, Hanada E, Satoh Y, Nakagawa K, Ishikawa Y, Fukui I. Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery. Int J Urol. 2005 Feb;12(2):208-10.
2. Yamanaka H, Ito K, Naito S, Tsukamoto T, Usami M, Fujimoto H, Matsuoka N, Fukui I, Harada M, Ohashi Y, Kotake T, Kakizoe T. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate. 2005 Apr 1;63(1):56-64.
3. Yoneda T, Adachi H, Urakami S, Kishi H, Shigeno K, Shiina H, Igawa M. Health related quality of life after orthotopic neobladder construction and its comparison with normative values in the Japanese population. J Urol. 2005 Nov;174(5):1944-7.
4. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005 Sep 15;11(18):6582-8.
5. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, Ogishima T, Okino ST, Li LC, Tanaka Y, Nonomura N, Okuyama A, Dahiya R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 2005 Aug 15;11(16):5793-801.
6. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA, Fujime M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene. 2005 Oct 13;24(45):6765-72.
7. Youssif M, Shiina H, Urakami S, Gleason C, Nunes L, Igawa M, Enokida H, Tanagho EA, Dahiya R. Effect of vascular endothelial growth factor on regeneration of bladder acellular matrix graft: histologic and functional evaluation. Urology. 2005 Jul;66(1):201-7.
8. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer. 2005 Aug 20;116(2):174-81.
9. Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll PR, Igawa M, Dahiya R. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res. 2005 Mar 15;65(6):2130-8.
10. Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urology. 2005 Mar;65(3):543-8.
11. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005 Feb 1;11(3):1028-36.
12. Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):557-64.
13. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, Nogawa M, Yuasa T, Kiyono Y, Wada H, Maekawa T. Cytotoxic effects of γδT cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer, 116: 94-99，2005.
14. Matsumoto S, Kimura S, Segawa S, Kuroda J, Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T, Wada H. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47: 31-9, 2005.
15. Yuasa T, Nogawa M, Kimura S, Yokota A, Sato K, Segawa H, Kuroda J, Maekawa T. A third generation bisphosphonate, minodronic acid (YM529), augments the interferon αβ-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res 11: 853-9, 2005.
16. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa S, Toda Y, Kageyama S, Yoshiki T, Okada Y, Maekawa T. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 115: 978-85, 2005.
17. Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, Sato K, Koizumi M, Maekawa T. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 15, 1-9, 2005.
18. Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, Yokota A, Maekawa T. Monitoring luciferase-labeled cancer cell growth and metastasis in in vivo models. Cancer Lett 217: 243-53, 2005.
19. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi, K, Maekawa T : NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106: 3948-3954, 2005.
20. Kataoka A, Yuasa T, Kageyama S, Iwaki H, Higuchi K, Tanaka T, Okada Y, Yoshiki T. Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer Oncol Rep 13, 597-600, 2005.
21. Yuasa T, Tsuji H, Kimura S, Niwa N, Yurugi K, Egawa H, Tanaka K, Maruya E, Saji H, Asano H, Maekawa T. HLA in Japanese patients with biliary atresia-a retrospective analysis in the patients with living donor liver transplantation-. Hum Immunl 66: 290-295, 2005.
22. Yuasa T, Niwa N, Kimura S, Tsuji H, Yurugi K, Egawa H, Tanaka K, Asano H, Maekawa T. Intraoperative blood loss during living donor liver transplantation: -an analysis of 635 recipients at a single center-Transfusion 45:879-884, 2005.
23. Segawa H, Kimura S, Kuroda J, Sato K, Nogawa M, Yuasa T, Yokota A, Hodohara K, Fujiyama Y, Maekawa T. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529. Leuk Res 29 451-7, 2005.
24. Segawa H, Kimura S, Kuroda, J, Sato K, Yokota A, Kawata E, Kamitsuji Y, Ashihara E, Yuasa T, Fujiyama Y, Ottmann OG, Maekawa T. Zoledronate synergizes with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth. Br J Haematol 130: 558-560 ,2005.
25. Kimura S, Yurugi K, Segawa H, Kuroda J, Sato K, Nogawa M, Yuasa T, Egawa H, Tanaka K, Maekawa T. Rapid Quantitation of IgG Antibodies Specific for Blood Group Antigens A and B by Surface Plasmon Resonanse. Transfusion 45: 56-62, 2005
26. Kimura S, Ito C, Jyoko N, Segawa H, Kuroda J, Okada M, Adachi S, Nakahata T, Yuasa T, Filho VC, Furukawa H, Maekawa T. Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from Calophyllim brasiliense that acts by induction of apoptosis. Int J Cancer 113: 158-65, 2005.